WO2024047130A1 - Immunosuppressive medicament and method of treatment - Google Patents
Immunosuppressive medicament and method of treatment Download PDFInfo
- Publication number
- WO2024047130A1 WO2024047130A1 PCT/EP2023/073842 EP2023073842W WO2024047130A1 WO 2024047130 A1 WO2024047130 A1 WO 2024047130A1 EP 2023073842 W EP2023073842 W EP 2023073842W WO 2024047130 A1 WO2024047130 A1 WO 2024047130A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- relaxin
- serum
- receptor
- equal
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims description 35
- 239000003814 drug Substances 0.000 title abstract description 10
- 230000001506 immunosuppresive effect Effects 0.000 title description 6
- 101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 claims abstract description 101
- 102100034949 Prorelaxin H2 Human genes 0.000 claims abstract description 60
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 37
- 208000014311 Cushing syndrome Diseases 0.000 claims abstract description 18
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims abstract description 18
- 239000003246 corticosteroid Substances 0.000 claims abstract description 13
- 230000001363 autoimmune Effects 0.000 claims abstract description 11
- 210000000056 organ Anatomy 0.000 claims abstract description 9
- 239000002395 mineralocorticoid Substances 0.000 claims abstract description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 63
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 63
- 210000002966 serum Anatomy 0.000 claims description 46
- 102000049116 human RLN2 Human genes 0.000 claims description 41
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 claims description 40
- 210000005007 innate immune system Anatomy 0.000 claims description 25
- 102000005962 receptors Human genes 0.000 claims description 25
- 108020003175 receptors Proteins 0.000 claims description 25
- 102000000849 HMGB Proteins Human genes 0.000 claims description 24
- 108010001860 HMGB Proteins Proteins 0.000 claims description 24
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 22
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 230000004054 inflammatory process Effects 0.000 claims description 20
- 230000028709 inflammatory response Effects 0.000 claims description 20
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 19
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 16
- 229940088597 hormone Drugs 0.000 claims description 15
- 239000005556 hormone Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000003831 deregulation Effects 0.000 claims description 14
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 230000000144 pharmacologic effect Effects 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 150000003431 steroids Chemical class 0.000 claims description 11
- 230000001629 suppression Effects 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 10
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 238000011275 oncology therapy Methods 0.000 claims description 10
- 201000008482 osteoarthritis Diseases 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 108700016890 S100A12 Proteins 0.000 claims description 9
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 8
- 208000001280 Prediabetic State Diseases 0.000 claims description 8
- 101150097337 S100A12 gene Proteins 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 8
- 230000001960 triggered effect Effects 0.000 claims description 8
- 201000005569 Gout Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010070308 Refractory cancer Diseases 0.000 claims description 5
- 208000025747 Rheumatic disease Diseases 0.000 claims description 5
- 208000007156 Spondylarthritis Diseases 0.000 claims description 5
- 201000002661 Spondylitis Diseases 0.000 claims description 5
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 5
- 201000001223 septic arthritis Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 206010062269 Adrenalitis Diseases 0.000 claims description 3
- 208000025721 COVID-19 Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 206010040628 Sialoadenitis Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000008105 immune reaction Effects 0.000 claims description 3
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 3
- 208000005963 oophoritis Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 208000001050 sialadenitis Diseases 0.000 claims description 3
- 206010043778 thyroiditis Diseases 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract description 29
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract description 26
- 230000006378 damage Effects 0.000 abstract description 13
- 229960001334 corticosteroids Drugs 0.000 abstract description 12
- 230000003511 endothelial effect Effects 0.000 abstract description 12
- 230000002411 adverse Effects 0.000 abstract description 10
- 230000004110 gluconeogenesis Effects 0.000 abstract description 10
- 238000002054 transplantation Methods 0.000 abstract description 9
- 230000006028 immune-suppresssive effect Effects 0.000 abstract description 6
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 206010011655 Cushingoid Diseases 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 2
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 102000003743 Relaxin Human genes 0.000 description 41
- 108090000103 Relaxin Proteins 0.000 description 39
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 34
- 229960003957 dexamethasone Drugs 0.000 description 31
- 239000002158 endotoxin Substances 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000004913 activation Effects 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 102000004971 Nuclear receptor coactivator 2 Human genes 0.000 description 17
- 108090001144 Nuclear receptor coactivator 2 Proteins 0.000 description 17
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 17
- 230000005779 cell damage Effects 0.000 description 16
- 208000037887 cell injury Diseases 0.000 description 16
- 210000003494 hepatocyte Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 208000014674 injury Diseases 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 206010063837 Reperfusion injury Diseases 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 102000013674 S-100 Human genes 0.000 description 11
- 108700021018 S100 Proteins 0.000 description 11
- 102000003952 Caspase 3 Human genes 0.000 description 10
- 108090000397 Caspase 3 Proteins 0.000 description 10
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 8
- 238000001768 microscale thermophoresis Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100029812 Protein S100-A12 Human genes 0.000 description 7
- 108020004459 Small interfering RNA Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 208000037816 tissue injury Diseases 0.000 description 7
- 102000011727 Caspases Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 6
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000013632 homeostatic process Effects 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 108020001756 ligand binding domains Proteins 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108010052500 Calgranulin A Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102100032442 Protein S100-A8 Human genes 0.000 description 5
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical compound C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 108010052495 Calgranulin B Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 3
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 101000869643 Homo sapiens Relaxin receptor 1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 3
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- 102100032444 Relaxin receptor 1 Human genes 0.000 description 3
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 3
- 102100023132 Transcription factor Jun Human genes 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- ZWGNFOFTMJGWBF-VZSHSMSCSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CC1=CN=CN1.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 ZWGNFOFTMJGWBF-VZSHSMSCSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101001091094 Homo sapiens Prorelaxin H1 Proteins 0.000 description 2
- 101000869654 Homo sapiens Relaxin receptor 2 Proteins 0.000 description 2
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 description 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 2
- 101710083978 Mixed lineage kinase domain-like protein Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100034945 Prorelaxin H1 Human genes 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 102100032445 Relaxin receptor 2 Human genes 0.000 description 2
- 108090000728 Relaxin receptors Proteins 0.000 description 2
- 101710113452 Relaxin-3 Proteins 0.000 description 2
- 102100034944 Relaxin-3 Human genes 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 102000051433 human GC Human genes 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960003248 mifepristone Drugs 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000021597 necroptosis Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000001089 thermophoresis Methods 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 102100032412 Basigin Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 101000602933 Danio rerio Nuclear receptor coactivator 2 Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150047053 GR gene Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 208000034706 Graft dysfunction Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 1
- 101001071608 Homo sapiens Glutathione reductase, mitochondrial Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910017621 MgSO4-7H2O Inorganic materials 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000025237 Polyendocrinopathy Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100032446 Protein S100-A7 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 1
- 241000607729 Salmonella enterica subsp. enterica serovar Abortus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100033077 TNF receptor-associated factor 2 Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000018254 acute transverse myelitis Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002482 anti-endothelial effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002800 anti-glucocorticoid effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000009548 growth disturbance Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 1
- 206010019680 hepatic infarction Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000012380 hydrogen-deuterium exchange experiment Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- -1 inflammatory Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000005914 myocardial expression Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
Definitions
- the present invention relates to medicinal preparations containing a low- molecular-weight peptide hormone of the human insulin superfamily and to medicinal preparations containing a Selective Glucocorticoid Receptor Modulator (SEGRM) dampening the innate immune system (A61 K 38/1754; A61 K 38/1751 ; A61 K 38/2221).
- SEGRM Selective Glucocorticoid Receptor Modulator
- Glucocorticoids are steroid hormones secreted by the adrenal glands. They regulate various physiological functions and are important in maintaining basal and stress- related homeostasis. In pharmacologic doses, glucocorticoids and corticosteroids are effective immunosuppressants in treating numerous inflammatory, autoimmune, and lymphoproliferative diseases. At the cellular level, the glucocorticoids and corticosteroids are functionally mediated by the glucocorticoid receptor (GR), which, simply put, is the receptor to which cortisol, cortisone, and glucocorticoids bind.
- GR glucocorticoid receptor
- the GR belongs to a receptor superfamily of nuclear transactivating factors with over 200 members and is ubiquitously expressed in almost all human tissues and organs.
- the GR is a hormone- and ligand-dependent transcription factor and regulates or affects GR-responsive genes' expression, which probably accounts for 3% to 10% of the human genome.
- the ligand-activated GR may upregulate the expression of anti-inflammatory proteins in the nucleus or inhibit the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol to the nucleus. Inhibition may also occur by the ligand-activated GR complex binding to the same site on the DNA where another transcription factor would bind so that the other no longer has an effect.
- the functions of the activated GR complexes are pleiotropic and occur in various parts of the body: in the control of metabolism, body development, and immune response. This has led to steroids and glucocorticoids becoming the most used drugs (see for review Nicolaides N et al., Glucocorticoid Receptor in Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet], South Dartmouth (MA): 2021).
- Relaxin was initially identified by its activity as a pregnancy hormone. Still, it not only has a function at the maternal-fetal interface (Hisaw FL in Experimental relaxation of the pubic ligament of the guinea pig, Proc. Soc. Exp. Biol. Med. 1926; 23:661-663). Relaxin is a heterodimeric peptide of about 6 kDa in which disulfide bridges like in insulin link an A chain and a B chain.
- the insulin superfamily includes insulin, insulin-like growth factors I and II, relaxin-1 , -2, and -3; and insulin-like factors 3, 4, 5, and 6.
- relaxin-2 is the primary stored form and the only form secreted into the circulation.
- relaxin-1 has been shown to act as an endocrine and paracrine factor that dilates blood vessels and increases blood flow in tissues (see for review: Dschietzig T et al. in Relaxin: a pregnancy hormone as a central player of body fluid and circulation homeostasis, CMLS 2003; 60:688-700; Dschietzig T et al. in Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics, Pharmacol Ther 2006; 112:38e56).
- relaxin has been observed to reduce oxidative cell damages that occur in orthotopic kidney and liver transplants and liver perfusion systems (DE102005040492; Boehnert MU in Relaxin as an additional protective model of isolate perfused rat liver, Ann N Y Acad Sci 2005, 1041 :434-440; Kageyama S et al. in Relaxin in Liver Transplantation: A Personal Perspective Mol Cell Endocrinol. 2019, 487: 75-79; Jakubauskiene L et al. in Relaxin positively influences ischemia-reperfusion injury in solid organ transplantation: a comprehensive review, Int J Mol Sci. 2020, 21 (2):631ff).
- glucocorticoids and GR activation are equally associated with specific adverse effects caused thereby.
- Adverse metabolic and pharmacologic effects of prolonged glucocorticoid treatment include wound healing disorders, manifestation/deregulation of diabetes mellitus, adverse immunosuppression, increased risk of infection, osteoporosis, growth disturbances in children as well as myopathy/muscular atrophy, skin atrophy, steroid acne, hirsutism in addition to the typical symptoms of a Cushing’s syndrome such as uncontrollable hypertension, disturbances of salt and water balance, psychological and neurological disorders, depression, etc.
- an individual benefit-risk analysis must be performed for each glucocorticoid therapy, primarily when treating cancer patients and transplant patients who receive such hormone therapy. This applies to patients suffering from a hormone-refractory type of tumor who are to be treated by a combination of a specific antibody and steroids to inhibit the proliferation of cancer cells. This is particularly true for patients who have a chronic inflammatory disease but for whom the harmful side effects of prolonged glucocorticoid treatment would outweigh the painful or debilitating effects of the underlying disease.
- the known prior art provides no guidance as to whether and when treatment with relaxin is medically justified. The prior art in this field, therefore, represents a problem.
- a pharmaceutical composition for treating a patient in need of a therapy dampening physiologic inflammatory reactions by the innate immune system comprising an effective amount of synthetic human relaxin-2 and a pharmacological solvent, diluent, or excipient.
- the patient suspected of requiring a dampening of physiologic inflammatory reactions by the innate immune system is tested for one or more of the following serum parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greater than or equal to 0.5 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, or serum calprotectin greater than or equal to 10 micrograms/ml.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- serum sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater than or equal to 10 micrograms/ml.
- a pharmaceutical composition for treating a patient suffering from inflammatory responses triggered by the innate immune system and/or requiring suppression through a ligand-activated glucocorticoid receptor which comprises as an active ingredient an effective amount of synthetic human relaxin-2 and a pharmacological solvent, diluent, or excipient, whereby manifestation or deregulation of diabetes or the symptoms of a Cushing’s syndrome are avoided.
- the patient suspected of having inflammatory responses triggered by the innate immune system has the following clinical criteria: prediabetes (HbA1 C > 5.7 and ⁇ 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher according to the 2017 ACC/AHA Guidelines).
- the pharmaceutical composition comprising an effective amount of synthetic human relaxin-2 is for treating a patient in need of an altered body or organ development while also preventing manifestation or deregulation of diabetes or symptoms of a Cushing’s syndrome. Said patient may already display have the following clinical characteristics: pre-diabetes (HbA1C > 5.7 and ⁇ 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher).
- the pharmaceutical composition comprising an effective amount of synthetic human relaxin-2 is for treating a patient having received an allotransplant and in need of a dampening of the innate immune system and inflammatory responses while preventing compromised wound healing, manifestation, or deregulation of diabetes or symptoms of a Cushing’s syndrome.
- Said medical need of a dampening of the innate immune system is given in case of a transplant patient when one or more of the following four criteria are fulfilled: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- serum sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater or equal to 4 micrograms/ml.
- the pharmaceutical composition comprising an effective amount of synthetic human relaxin-2 is for treating a patient in need of chronic suppression of the innate immune system and inflammatory responses while preventing manifestation or deregulation of diabetes or symptoms of a Cushing’s syndrome.
- said patient suspected of requiring a chronic suppression of inflammatory reactions manifests one or more medical criteria selected from serum HMGB1 (high-mobility group box protein) greaterthan or equal to 4 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greaterthan or equal to 0.5 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- serum sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater than or equal to 10 micrograms/ml.
- said pharmaceutical composition is for treating a patient in need of hormone-refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy through a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers; Kaposi Sarcoma, the synthetic human relaxin-2 being used as supplement and substitute of the glucocorticoid receptor activating hormone.
- hormone-refractory cancer therapy including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy through a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers; Kaposi Sarcoma, the synthetic human relaxin-2 being used as supplement and substitute of the glucocorticoid receptor activating hormone.
- Another aspect of the invention relates to a method of treating a patient which comprises testing said patient for one or more of the following clinical parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greaterthan or equal to 0.5 ng/ml; serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml, and when given, administering to the patent an effective amount of synthetic human relaxin-2 within a pharmacological solvent, diluent, or excipient to dampen or suppress physiologic inflammatory reactions by the innate immune system.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- serum sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater than
- said method steps are used for treating a patient suffering from inflammatory responses triggered by the innate immune system and/or requiring suppression through a ligand-activated glucocorticoid receptor, wherein the active pharmacological ingredient is synthetic human relaxin-2 to avoid a manifestation or deregulation of diabetes or the symptoms of a Cushing’s syndrome.
- said method of treatment comprises administering an effective amount of synthetic human relaxin-2 a patient in need of an altered body or organ development while preventing manifestation or deregulation of diabetes or symptoms of a Cushing’s syndrome.
- the method comprises administering an effective amount of synthetic human relaxin-2 to a patient who has received an allograft and requires suppression of innate immune and inflammatory responses without compromising wound healing, manifesting or deregulating diabetes, or inducing symptoms of a Cushing’s syndrome, after testing the transplant patient positive on one or more of the following medical criteria: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater or equal to 4 micrograms/ml.
- the method of treatment comprises administering an effective amount of synthetic human relaxin-2 to a patient diagnosed as needing hormone- refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy by a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers, Kaposi’s sarcoma, wherein the synthetic human relaxin-2 is used to supplement and/or replace glucocorticoid receptoractivating hormone.
- the method comprises administering an effective amount of synthetic human relaxin-2 to a patient who requires an extra or substitute for a glucocorticoid receptor activating hormone.
- the method of treatment comprises administering an effective amount of synthetic human relaxin-2 to a patient diagnosed as needing immunosuppressive therapy, wherein the synthetic relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone to prevent or avoid a manifestation or deregulation of diabetes or symptoms of Cushing’s syndrome, mainly when the patient displays one or more of the following clinical features: pre-diabetes (HbA1C > 5.7 and ⁇ 6.5 %), obesity (BMI > 30 kg/m2), hypertension (Level 1 or higher according to the 2017 ACC/AHA guidelines).
- the patient is initially diagnosed as requiring chronic doses of corticosteroids and/or glucocorticoids and it comprises subcutaneously administering an appropriate amount of synthetic human relaxin-2 thereby avoiding a manifestation or deregulation of diabetes, wound healing disorders, or the symptoms of Cushing’s syndrome.
- the patient suffers from forms of autoimmune or rheumatic diseases; ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA) and inflammatory types of arthritis, rheumatoid arthritis (RA).
- AS ankylosing spondylitis
- OA osteoarthritis
- PsA psoriatic arthritis
- RA rheumatoid arthritis
- the method comprises testing the patient for one or more of the following clinical parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greater than or equal to 0.5 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml, and when given, administering to the patent an effective amount of synthetic human relaxin-2 within a pharmacological solvent, diluent, or excipient to dampen or suppress physiologic inflammatory reactions by the innate immune system.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- serum sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater than or equal to 10 micrograms/ml
- the method comprises treating a patient suffering from SIRS (systemic inflammatory response syndrome), autoimmune or rheumatic diseases, thyroiditis, gastritis, insulitis, sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, polyarthritis, ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA) and inflammatory types of arthritis, rheumatoid arthritis (RA), SARS-Covid 19 und SARS.
- SIRS systemic inflammatory response syndrome
- autoimmune or rheumatic diseases thyroiditis, gastritis, insulitis, sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, polyarthritis, ankylosing spondylitis (AS) and spondy
- the method comprises treating a patient suffering from immunological reactions by the innate immune system and/or displays the following clinical criteria: pre-diabetes (HbA1C > 5.7 and ⁇ 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher according to the 2017 ACC/AHA Guidelines).
- the method comprises treating a patient suffering from inflammatory responses triggered by the innate immune system and/or requires suppression of inflammatory responses through a ligand- activated glucocorticoid receptor, wherein the active pharmacological ingredient is synthetic human relaxin-2 to avoid a manifestation or deregulation of diabetes, wound-healing disturbance, and/or the symptoms of Cushing’s syndrome.
- the method comprises treating a patient who has received an allograft and requires suppression of the innate immune system and inflammatory responses, after testing the patient positive on one or more of the following medical criteria: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml.
- serum HMGB1 high-mobility group box protein
- serum sTLR4 soluble Toll-like receptor-4
- serum sRAGE soluble receptor of advanced glycation end-products
- serum calprotectin greater or equal to 4 micrograms/ml.
- the method comprises treating a patient who is in need of hormone-refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy by a ligand- activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers, Kaposi’s sarcoma, wherein synthetic human relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone.
- hormone-refractory cancer therapy including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy by a ligand- activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers, Kaposi’s sarcoma
- synthetic human relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone.
- the method comprises treating a patient diagnosed as requiring immunosuppressive therapy, wherein synthetic relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone to prevent or avoid a manifestation or deregulation of diabetes or symptoms of Cushing’s syndrome, particularly when the patient displays one or more of the following clinical features: pre-diabetes (HbA1C > 5.7 and ⁇ 6.5 %), obesity (BMI > 30 kg/m2), hypertension (Level 1 or higher according to the 2017 ACC/AHA guidelines).
- Fig. 1 is a diagram showing a microscale thermophoresis of the high-affinity binding (KD ⁇ 5 nM) of H2 relaxin to helix 12 of the ligand-binding domain of the human GC receptor in the absence of the co-activator TIF2.
- Fig. 2 is a diagram of a microscale thermophoresis showing the lower affinity interaction (KD ⁇ 500 nM) of H2 relaxin to the ligand-binding domain of the human GC receptor.
- Fig. 3 is a data plot of the release of lactate dehydrogenase (LDH) from cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury); induction by H2O2; induction by H2O2 after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); after knockdown of the GC receptor by added siRNA (GRsi) and scrambled siRNA (scr) as a control - all data in percent of detergent-induced maximal cytotoxicity.
- GRsi lactate dehydrogenase
- scr scrambled siRNA
- FIG. 4 is a data plot of the release of cleaved caspase-3 from cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury); cell injury by H2O2; after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); after knockdown of the GC receptor by addition of siRNA (GRsi) and scrambled siRNA (scr) as a control - all data normalized to p-actin and adjusted to the effect of H2O2.
- Control no cell injury
- H2O2 cell injury by H2O2
- Dx dexamethasone
- GRsi siRNA
- scr scrambled siRNA
- Fig. 5 is a data plot comparing the relative amounts of cytosolic GC receptor (GR) in cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury), by addition of H2O2; after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); relaxin-2 or dexamethasone alone - all data normalized to control.
- GR cytosolic GC receptor
- Fig. 6 is a data plot comparing the relative amounts of mitochondrial pyruvate dehydrogenase lipoamide kinase isoenzyme 4 (PDK-4) in cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury), cell injury by addition of H2O2; cell injury after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); added relaxin-2 or dexamethasone alone - all data normalized to control.
- PDK-4 mitochondrial pyruvate dehydrogenase lipoamide kinase isoenzyme 4
- Fig. 7 is a data plot comparing concentrations of tumor necrose factor-alpha (pg/mL) - an adipokine and cytokine - in the supernatants of activated Th1-macrophages: Control (no activation); activation by lipopolysaccharides (endotoxin); after treatment of macrophages with relaxin-2 (Rix) or dexamethasone (Dx) or Mifepristone-RU486 (RU) or LPS+Rlx+RU486 or LPS+Dx+RU486.
- Fig. 8 is a data plot comparing concentrations of interleukin-6 (pg/mL) - pro-inflammatory cytokine - in the supernatants of activated Th1-macrophages: Control (no activation); activation by lipopolysaccharides (endotoxin); after treatment of macrophages with relaxin-2 (Rix) or dexamethasone (Dx) or Mifepristone-RU486 (RU) or LPS+RIX+RU486 or LPS+Dx+RU486.
- Fig. 9 is a data plot comparing concentrations of circulating tumor necrose factor alpha (pg/mL) in blood from rats 24 hours after challenge with E. coli endotoxin: Control (placebo - no endotoxin); challenge with E.coli endotoxin (125 pg LPS I kg body weight); 2 hours after continuous sc. infusion (4 pg/h) of synthetic relaxin-2 (Relaxera Pharmazeutician GmbH, DE); i.m. injection of dexamethasone (10 mg/kg); oral RU- 486 (single dose of 10 mg /kg body weight) or combinations thereof;
- Fig. 10 is a data plot comparing concentrations of fasting blood sugar levels (24 hours) in rats after exposure to E. coli endotoxin: control (placebo - no endotoxin); challenge with E. coli endotoxin (125 pg LPS I kg body weight); challenge 2 hours after continuous subcutaneous infusion (4 pg/h) of synthetic relaxin-2 (Relaxera Pharmazeutician GmbH, Bensheim, DE); intramuscular injection of dexamethasone (10 mg/kg im.; oral RU-486 (single dose of 10 mg /kg body weight) or combinations thereof.
- Fig. 11 is a data plot comparing concentrations of fasting blood sugar levels (48 hours) in blood from rats after challenge with E. coli endotoxin: Control (placebo - no endotoxin); challenge with E. coli endotoxin (125 pg LPS I kg body weight); challenge 2 hours after continuous sc. infusion (4 pg/h) of synthetic relaxin-2 (Relaxera, Bensheim, DE); intramuscular injection of dexamethasone (10 mg/kg); oral RU-486 (single dose of 10 mg /kg body weight) or combinations thereof.
- Fig. 12 is a data plot comparing the percentage of T reg macrophages (CD4+CD25+ regulatory T cells) in blood from rats after continuous sc. infusion (4 pg/h) of relaxin-2 or oral RU- 486 (single dose of 10 mg /kg body weight) or both - all data as a percentage of the total white blood cell count (WBC).
- glucocorticoids Millions of patients take glucocorticoids to treat autoimmune and rheumatoid diseases, neurological disorders, pulmonary diseases, cancer, and other diseases and causes.
- the chronic side effects of glucocorticoids and their adverse consequences are much feared, particularly the negative impact due to glucocorticoid receptor (GR) down-regulation, steroid-induced hyperglycemia, or activation of gluconeogenesis as well as Cushing’s syndrome.
- GR glucocorticoid receptor
- the present inventors have discovered that relaxin-2 binds the ligand-binding domain of the GR like steroids and glucocorticoids, forming an activated GR-ligand complex.
- the relaxin-GR complex activates the transcription of genes dampening the innate immune system but no genes activating gluconeogenesis, unlike the glucocorticoids or corticosteroids.
- This discovery enlarges the therapeutic applications of relaxin-2 for patients in need of a dampened innate immune system.
- This group of patients comprises for example patients who receive or have received an allotransplant, and cancer patients.
- tissue/endothelial injury or tissue-damaging diseases including autoimmune or rheumatic tissue-damaging diseases comprising ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA), and inflammatory types of arthritis, rheumatoid arthritis (RA).
- Medications for these diseases include corticosteroids, oral and topical analgesics, non-steroidal anti-inflammatory drugs such as ibuprofen and COX-2 inhibitors, and disease-specific biologies.
- the calcium-binding S100 proteins are released from the cytoplasm of the endothelial cell when triggered by tissue/cell damage, antibody stress, and endothelial stress.
- the S100 proteins then serve as danger signals, DAMP (damage-associated molecular pattern) molecules, and are involved in the regulation of immune homeostasis (macrophage migration, invasion, and differentiation), post-traumatic injury, and inflammation. They are therefore biomarkers in some specific diseases such as IBD (inflammatory bowel disease), although their multiple functions must be assigned to cell migration, differentiation, tissue repair, immune homeostasis, and inflammation management.
- DAMP damage-associated molecular pattern
- IBD inflammatory bowel disease
- relaxin-2 not only binds to the glucocorticoid receptor as shown in Fig. 1 but that the experimental results in Fig. 12 further indicate that the administration of relaxin-2 leads to a specific activation and promotion of regulatory T cells at local and systemic levels, likely induced by the relaxin-GR complex. This allows suppression of immune responses and significantly widens the use of relaxin-2 as an active ingredient in pharmaceuticals for treating abnormal, excessive, and undesired tissuedamaging immune responses to self- and foreign antigens.
- Treg cells Regulatory T cells
- CD25 interleukin-2 receptor a-chain
- the regulatory T cells are further classified into thymic and peripherally induced Treg cells based on where they develop.
- the Foxp3 gene a member of the Forkhead/winged-helix family of transcriptional regulators, was discovered to be an important regulator in the development of Treg cells based on the following findings: Scurfy mice with a frameshift mutation in the Foxp3 gene have T cell inflammation in multiple organs and a lethal autoimmune disease due to effector T cell activation and increased cytokine production caused by the absence of Treg cells.
- CD4/CD25-naive T cells transfected with the Foxp3 gene can transform into CD4 + CD25 + Treg-like cells that produce inhibitory cytokines and express typical Treg-cell molecules such as CD25, cytotoxic T-lymphocyte antigen-4 (CTLA-4), and glucocorticoid- induced tumor necrosis factor (TN F) receptor-related protein (GITR).
- CTL-4 cytotoxic T-lymphocyte antigen-4
- TN F glucocorticoid- induced tumor necrosis factor receptor-related protein
- FoxP3 is a lineagespecific marker and an important regulatory gene for the generation, maintenance, and immune suppressive functions of Treg cells.
- Regulatory T cells are required to suppress abnormal or excessive immune responses and to maintain homeostasis and self-tolerance by inhibiting T cell proliferation and cytokine production.
- the Treg cells exert their immunosuppressive function through dominant consumption of the cytokine interleukin-2 and by inhibitory cytokines (TGF-B, IL-10, IL-35) as well as induction of apoptosis or a killing of effector or antigen-presenting cells (APC) by perforin, granzyme B or Fas ligand interaction.
- TGF-B inhibitory cytokines
- APC antigen-presenting cells
- Treg cells involve immune checkpoint molecules and include inhibition of effector T cells by the lymphocyte activation programmed cell death pathways or the cytotoxic T-lymphocyte antigen (CTLA-4).
- CTLA-4 cytotoxic T-lymphocyte antigen
- a third immunosuppressive mechanism may be metabolic modulation by indoleamine 2,3- dioxygenase (IDO) expression, which affects the kynurenine-tryptophan pathway in dendritic cells.
- IDO indoleamine 2,3- dioxygenase
- the Treg cells thereby play a critical role in suppressing autoimmunity and inflammation. Reduced number and function of Treg cells are associated with human autoimmune disease, and activation and augmentation of Treg cells have been shown to be beneficial in treating autoimmune diseases in clinical trials (see the review of Margarita Dominquez-Vallar & David A.
- Treg cells contribute to the maintenance of selftolerance by downregulating the immune response to self and foreign antigens in an antigen- nonspecific manner. Therefore, it is reasonable to hypothesize that a relaxin-2-induced increase in Treg cells in a posttransplant patient also improves post-transplant outcomes beyond the prevention of ischemic injury. The very same can also be assumed when relaxin- 2 is used in treating autoimmune induced tissue injury, endothelial cell injury and diseases following endothelial cell activation. The hypothesis is also supported by the fact that a reduction in the proportion of Treg cells in the peripheral blood is known to lift general immune suppression, thereby enhancing the innate and acquired immune response to foreign and selfantigens. Therefore, the present discovery significantly expands the pharmaceutical toolbox.
- Fig .1 and Fig. 2 refer to in vitro binding and affinity studies of synthetic human relaxin-2 (shRIx) to the ligand-binding domain of the glucocorticoid receptor (GR-LBD) using microscale thermophoresis (MST).
- the microscale thermophoresis is based on measuring the directed movement of molecules in localized temperature gradients created by IR laser radiation in high-precision glass capillary tubes containing the interacting partners - synthetic human relaxin-2 and recombinant GR-LBD.
- the human glucocorticoid receptor (GR-LBD) ligand-binding domain was expressed in an E. coli expression system to obtain a large amount of soluble protein stable for biophysical characterization.
- the recombinantly produced GR-LBD showed little aggregation and proved to be fully functional.
- One of the interacting partners was labeled with a fluorescent dye and added to a serial dilution series (15 dilutions each) of the non-fluorescent partner. After incubation, the thermophoretic movement of the complex is detected. Conformational changes due to ligand binding to the target or binding near the fluorophore induce thermophoretic changes.
- the affinity of interacting protein is determined by analyzing the change in normalized fluorescence as a function of the concentration of titrated binding partner. The next step was to determine the binding mode of relaxin and the activation mechanism of GR. Fluorescence polarisation revealed two binding affinities in the pico- and nanomolar range.
- human H2 relaxin could displace fluormone labeled GS red out of its binding pocket on GR-LBD (see method described by Hemmerling M et al. in Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases, J. Med. Chem. 2017, 60, 20, 8591-8605).
- MST microscale thermophoresis
- HDX- MS hydrogen-deuterium exchange mass spectrometry
- NMR NMR
- GR-LBD has an activation function-2 site that will recruit cofactors upon ligand binding.
- the cofactors are specific to the cellular environment. Therefore, the binding of relaxin with coactivator and corepressor motifs to the GR-LBD/relaxin complex was tested.
- thermophoresis is an intrinsic phenomenon of a molecule that depends on the hydration shell and the size, the binding events could be identified by tracking the associated changes to thermophoresis in a fluorescently labeled interacting partner.
- the results of the microscale thermophoresis indicate a high- affinity interaction (KD ⁇ 5 nM) and another lower-affinity interaction (KD ⁇ 500 nM) of synthetic human relaxin-2 with the GR-LBD.
- NCoA-2 contains several nuclear receptor interacting domains and intrinsic histone acetyltransferase activities, and when GR recruits NCoA-2 to a DNA promotion site, the role of NCoA-2 also appears to be in acetylating histones so that the downstream DNA becomes more accessible for transcription. The presence and amount of NCoA-2 are cell-type dependent. NCoA2 (GRIP1 , SRC-2, TIF2) therefore supports up-regulation of DNA expression which also leads to increased activation of genes responsible for gluconeogenesis. Since human relaxin-2 does not recruit NCoA-2 upon binding, this type of gene activation does not appear to be triggered when human relaxin- 2 binds to the glucocorticoid receptor.
- GRIP1 glucocorticoid receptor-interacting protein 1
- SRC-2 steroid receptor coactivator-2
- TIF2 transcription intermediary factor 2
- mice hepatocytes were isolated as described by Tamaki N et al. in Am J Physiol Gastrointest Liver Physiol 2008 294, G499. Briefly, livers from mice anesthetized with pentobarbital were washed and perfused for 5 min with buffer consisting of (all values are mg/L) 8,000 NaCI, 400 KCI, 88,7 NaH2PO 4 H2O, 120.45 Na 2 HPO 4 , 2,380 HEPES, 350 NaHCO 3 , 190 EGTA, and 900 glucose, pH 7.25, then treated with 0.03% collagenase at 37°C for 15 min in digestion buffer containing (all values are mg/L) 8,000 NaCI, 400 KCI, 88.7 NaH 2 PO 4 H 2 0, 120.45 Na 2 HPO 4 , 2,380 HEPES, 350 NaHCO 3 , and 560 CaCl2'2H2O , pH 7.25.
- GBSS Geys balanced salt solution
- Isolated mouse hepatocytes were cultured on type I collagen-coated 6-well plates coated at a cell density of 5 x 10 5 cells/well with Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 U/ml penicillin, and 100 pg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2-95% air. After plating, the medium was replaced with serum- free Dulbecco's modified Eagle medium after 6 hours.
- hepatocytes were then subjected to hydrogen peroxide treatment (2 mM H2O2/L) for 5 hours with or without pretreatment with synthetic human relaxin-2 (10 nM/L, 24 h) (Relaxera Pharmazeutician GmbH, Bensheim, DE) or dexamethasone (0,5 mM, 24 h) (Sigma Aldrich).
- synthetic human relaxin-2 (10 nM/L, 24 h) (Relaxera Pharmazeutician GmbH, Bensheim, DE) or dexamethasone (0,5 mM, 24 h) (Sigma Aldrich).
- H2O2-induced cell injury was determined immunologically by quantification of lactate dehydrogenase (LDH) released into the culture medium using an enzyme-linked assay according to the manufacturer’s instructions (Goat LDH ELISA kit, Biomol Feinchemikalien GmbH, DE) and by Western Blot analysis of cleaved caspase-3 (Caspase-3 Rabbit mAb #14220, Cell Signaling Technology, Danvers, MA, US).
- LDH lactate dehydrogenase
- LDH is an enzyme expressed in nearly all living cells, including heart muscles and blood cells, and it catalyzes the conversion of lactate to pyruvate and back. Because it is released during tissue injury, it is a marker of common injuries, damaged tissues, and diseases involving tissue damage such as heart failure. In contrast, the relative concentrations of its substrates primarily regulate LDH activity. LDH is subject to transcriptional regulation by peroxisome proliferator-activated receptor-y coactivator 1a (PGC-1a) in an estrogen-related receptor-a-dependent manner.
- POC-1a peroxisome proliferator-activated receptor-y coactivator 1a
- Caspase 3 protein (CASP3) or cysteine-dependent aspartate-directed protease 3 plays an essential role in programmed cell death.
- Caspase-3 is synthesized as an inactive zymogen until cleaved after apoptotic signaling events.
- Caspase-3 is thought to ensure that cellular components are degraded in a controlled manner, and that cell death occurs with minimal impact on surrounding tissues.
- Caspase deficiency has been identified as a cause of tumor development, for example, by a mutation in a cell cycle gene that removes cell growth restrictions in combination with mutations in apoptotic proteins such as caspases that would trigger cell death in abnormally growing cells.
- caspase-3 can lead to excessive programmed cell death. This is seen in several neurodegenerative diseases in which neural cells are lost, such as Alzheimer's disease. Caspases involved in processing inflammatory signals are also implicated in disease. Insufficient caspase activation can increase an organism's susceptibility to infection because an appropriate immune response may not be triggered. For example, inflammatory caspase-1 has been linked to the development of autoimmune diseases; drugs that block caspase activation have been used to improve patients’ health.
- Fig. 5 shows that relaxin-2 increases GR gene transcription in normal and H2O2-stressed primary mouse hepatocytes by 100% to 200 %, whereas dexamethasone has no such effect.
- Fig. 6 shows that the incubation with relaxin-2 has no effect on PDK-4 gene transcription in normal and H2O2-stressed primary mouse hepatocytes.
- primary mouse hepatocytes are incubated with dexamethasone, PDK-4 gene transcription increases severalfold.
- the combination of Figs. 5 and 6 is therefore strong evidence that the complex of relaxin and GR binds to a genomic DNA locus that is different from the DNA locus of steroid-activated GR.
- PDK-4 pyruvate dehydrogenase lipoamide kinase isozyme 4
- PDH pyruvate dehydrogenase complex
- An active PDH complex is required to convert pyruvate to acetyl-CoA for the glycolytic products to enter the citric acid cycle.
- Fasting results in an induction of PDK-4 mRNA and PDK-4 enzyme in both cardiac and skeletal muscle, suppressing glucose oxidation during starvation as part of an integrative response and for glucose maintenance.
- the PDK-4 enzyme is therefore thought to play a critical role in regulating glucose metabolism, whereas an increased PDK-4 transcription indicates gluconeogenesis. It is well known that PDK-4 expression is physiologically regulated by glucocorticoids, retinoic acid, and insulin which enhance the transcription of the PDK-4 gene in white adipose tissue. Oxidation of fatty acids is also increased when the PDK-4 level is elevated. Insulin downregulates PDK-4 mRNA transcription. When cells are exposed to dexamethasone to increase PDK-4 mRNA expression, insulin blocks this effect and the oxidation of fatty acids. In type 2 diabetes, PDK-4 is overexpressed in skeletal muscle, resulting in impaired glucose utilization.
- PDK-4 mRNA expression is also markedly decreased in association with increased glucose uptake, likely due to the downregulation of PDK-4 by insulin. This is consistent with the hypothesis that fatty acid availability affects glucose metabolism by regulating the pyruvate dehydrogenase (PDH) complex. Indeed, in insulin-resistant individuals, an inadequate downregulation of PDK-4 mRNA may cause increased PDK-4 expression, leading to impaired glucose oxidation followed by increased fatty acid oxidation. Conversely, PDK-4 is downregulated in cardiac muscle tissue during heart failure, which is a physiological countermeasure (Razeghi P et al., in Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading, Cardiology 2002, 97(4):203-9).
- Figs. 3 through 6 show that relaxin-2 like glucocorticoids, corticosteroids, and mineralocorticoids has anti-inflammatory effects, but without leading to impaired glucose oxidation, increased fatty acid oxidation, and gluconeogenesis.
- the ubiquitous role of PDK-4 further suggests that a pharmaceutical composition containing relaxin-2 and treatment with relaxin-2 may be an alternative to glucocorticoid treatment because it results in increased expression of the glucocorticoid receptor, which suppresses immune and inflammatory responses, but not in increased expression of PDK-4, which is unfavorable for glucose metabolism and balance.
- the glucocorticoid receptor is an evolutionarily conserved liganddependent transcription factor. Upon binding of a steroid hormone or other ligand, the receptor migrates from the cytoplasm to the nucleus where it binds to a genomic DNA locus and positively or negatively modulates the transcription rates of the locus-associated genes. Tremendous efforts have been made to uncover the molecular signaling actions of the GR, including intracellular shuttling, transcriptional regulation, and interaction with other intracellular signaling pathways. In brief, glucocorticoids are essential for the maintenance of resting-state and stress response and, therefore, they are essential in the treatment of numerous diseases, including autoimmune, inflammatory, allergic, and lymphoproliferative disorders. The pathological or therapeutic implications of the GR cannot be overstated. These include, except for genetic alterations in the human GR gene, disease-associated GR regulatory molecules and the development of GR ligands with selective GR action.
- Figs. 1 to 6 show that the administration of synthetic relaxin-2 has therapeutic effects that differ from known corticosteroids and glucocorticoids.
- the experiments presented demonstrate that synthetic relaxin-2 elicits GR-dependent glucocorticoid effects, including inhibition of apoptosis in mouse hepatocytes and inhibition of cytokine release in human macrophages (see example 4 below), which, in contrast to classical corticosteroids and glucocorticoids, avoid unwanted effects such as GR down-regulation or glucocorticoid- or steroid-induced hyperglycemia or activation of gluconeogenesis.
- EXAMPLE 4 - Relaxin-2 dampens the release of pro-inflammatory cytokines
- THP-1 cells were differentiated into macrophages and cultured as described by Dschietzig T et al. in Identification of the pregnancy hormone relaxin as a glucocorticoid receptor agonist, FASEB J 2004, 18:1536-1538. Briefly, the THP-1 cells are derived from a cell line generated from a human monocyte leukemia, and when the cells are treated in the passage with myristate-phorbol ester, they differentiate into macrophages as is well known in the art.
- RU-486 also known as Mifepristone®, is a steroidal antiprogesterone as well as an antiglucocorticoid and antiandrogen. It competitively antagonizes cortisol action at the GR receptor.
- an antiglucocorticoid effect of RU- 486 is observed at doses greater or equal to 4.5 mg/kg through a compensatory increase in adrenocorticotropic hormone (ACTH) and cortisol.
- ACTH adrenocorticotropic hormone
- animals a weak antiandrogenic effect is seen with prolonged administration of very high doses (Danco Laboratories, 2005, Mifeprex U.S. prescribing information).
- this example demonstrates that the administration of synthetic human relaxin-2 can provide GR-mediated regulation of the immune system, and has immune-suppressive properties, but without the side effects of inducing gluconeogenesis and insulin insensitivity.
- Figs. 9, 10, and 11 refer to animal experiments and show the different effects of relaxin-2 and dexamethasone (Sigma Aldrich) administration on blood glucose levels in rats after 24 and 48 hours.
- relaxin-2 and dexamethasone Sigma Aldrich
- Figs. 9, 10, and 11 refer to animal experiments and show the different effects of relaxin-2 and dexamethasone (Sigma Aldrich) administration on blood glucose levels in rats after 24 and 48 hours.
- E coli endotoxin 125 pg/kg body weight
- placebo placebo
- Blood from the tail vein was taken after 24 hours for the determination of circulating TNF-a (ELISA, R&D Systems) and fasting blood glucose and at 48 hours for measurement of fasting blood glucose.
- EXAMPLE 5 Relaxin-2 furthers differentiation of naive T cells into regulatory T cells (Treg) in mice similar to glucocorticoids
- mice of C57BI/6 background were intraperitoneally injected once daily for 3 consecutive days in the following experimental groups: synthetic human relaxin-2 (Relaxera) (10 micrograms/kg body weight), placebo (vehicle, sodium acetate), RU- 486 (2.5 mg/kg body weight), relaxin-2 plus RU-486. Thereafter, mice were sacrificed, their spleens were processed using standard procedures, and the percentage of spleen regulatory T cells (Treg) was analyzed by FACS. T reg cells were originally defined as characterized as CD4+FoxP3+ cells wherein FoxP3 (a Forkhead transcription factor) is the T reg master regulator. Regulatory T cells expressing the transcription factor Forkhead box P3 (FoxP3) are known to control immune responses and prevent autoimmunity.
- Relaxera synthetic human relaxin-2
- placebo vehicle, sodium acetate
- RU- 486 2.5 mg/kg body weight
- relaxin-2 plus RU-486 relaxin-2 plus RU-486.
- glucocorticoids and corticosteroids are mainstays in the treatment of tissue-damaging autoimmune pathologies such as rheumatoid arthritis, and they are immunosuppressants following organ transplantation.
- the calcium-binding S100 proteins are universal markers for inflammation and of the innate immune system, notably calprotectin (the complex of S100A8 and S100A9) as well as S100A12.
- calprotectin the complex of S100A8 and S100A9
- S100A12 and calprotectin indicate tissue injury, endothelial cell activation, and inflammation-mediated responses.
- AP1 activator protein 1
- ERK extracellular signal-regulated protein kinase
- GPCR G-protein-coupled receptor
- IL-1 interleukin 1
- IL-7 interleukin 7
- IKBO interleukin 1
- JNK c-Jun N-terminal kinase
- P38 mitogen-activated protein kinase
- S100 proteins When released to the extracellular space, S100 proteins have activities in the regulation of immune homeostasis, post-traumatic injury, tissue damage, and inflammation. S100 proteins trigger inflammation through interacting with receptors RAGE and TLR4, and there is evidence that calprotectin (S100A8/S100A9) is an endogenous agonist of TLR4. Binding to TLR4 initiates a signaling cascade and regulates inflammation, cell proliferation, and differentiation in an NFKB- dependent manner.
- S100 proteins such as S100A7, S100A12, S100A8/A9 (calprotectin), and SWOB.
- S100 proteins activate NFKB, inducing the production of pro-inflammatory cytokines leading to the migration of neutrophils, monocytes, and macrophages.
- Extracellular S100 proteins are therefore involved in the regulation of cell apoptosis, migration of monocytes, macrophages, neutrophils, lymphocytes, myoblasts, epithelial cells, and endothelial cells. Consequently, the levels of S100A8/A9 complex (calprotectin) and S100A12 in extracellular fluids can be used as biomarkers to assess the degree of inflammatory regulation and tissue injury.
- RIPK1 receptor-interacting serine/threonine-protein kinase 1
- RIPK1 receptor-interacting serine/threonine-protein kinase 1
- MLKL mixed lineage kinase domain-like protein
- TNF tumor necrosis factor
- relaxin-2 has been described for its antifibrotic, antioxidant, anti-inflammatory, and cytoprotective properties, there was no evidence that relaxin-2 can be used beneficially as a substitute for glucocorticoids without inducing their Cushingoid adverse effects, particularly gluconeogenesis, and its promotion of immune suppressive Treg cells was also not observed, which, however, makes relaxin-2 a broad-spectrum drug for tissue and endothelial injury, rather than a vasodilator additive in a perfusion solution to prevent ischemia-reperfusion injury.
Abstract
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and cushingoid adverse effects. Medicament and treatment for supporting the repair of tissue and endothelial injuries by a promotion of immune suppressive regulatory T cells (Treg), particularly, in case of autoimmune pathologies and organ transplantation.
Description
IMMUNOSUPPRESSIVE MEDICAMENT AND METHOD OF TREATMENT
FIELD OF THE INVENTION
(001) The present invention relates to medicinal preparations containing a low- molecular-weight peptide hormone of the human insulin superfamily and to medicinal preparations containing a Selective Glucocorticoid Receptor Modulator (SEGRM) dampening the innate immune system (A61 K 38/1754; A61 K 38/1751 ; A61 K 38/2221).
BACKGROUND OF THE INVENTION
(001) Glucocorticoids are steroid hormones secreted by the adrenal glands. They regulate various physiological functions and are important in maintaining basal and stress- related homeostasis. In pharmacologic doses, glucocorticoids and corticosteroids are effective immunosuppressants in treating numerous inflammatory, autoimmune, and lymphoproliferative diseases. At the cellular level, the glucocorticoids and corticosteroids are functionally mediated by the glucocorticoid receptor (GR), which, simply put, is the receptor to which cortisol, cortisone, and glucocorticoids bind. The GR belongs to a receptor superfamily of nuclear transactivating factors with over 200 members and is ubiquitously expressed in almost all human tissues and organs. The GR is a hormone- and ligand-dependent transcription factor and regulates or affects GR-responsive genes' expression, which probably accounts for 3% to 10% of the human genome. For example, the ligand-activated GR may upregulate the expression of anti-inflammatory proteins in the nucleus or inhibit the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol to the nucleus. Inhibition may also occur by the ligand-activated GR complex binding to the same site on the DNA where another transcription factor would bind so that the other no longer has an effect. The functions of the activated GR complexes are pleiotropic and occur in various parts of the body: in the control of metabolism, body development, and immune response. This has led to steroids and glucocorticoids becoming the most used drugs (see for review Nicolaides N et al., Glucocorticoid Receptor in Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet], South Dartmouth (MA): 2021).
(002) Relaxin was initially identified by its activity as a pregnancy hormone. Still, it not only has a function at the maternal-fetal interface (Hisaw FL in Experimental relaxation of the pubic ligament of the guinea pig, Proc. Soc. Exp. Biol. Med. 1926; 23:661-663). Relaxin is a heterodimeric peptide of about 6 kDa in which disulfide bridges like in insulin link an A chain and a B chain. The insulin superfamily includes insulin, insulin-like growth factors I and II, relaxin-1 , -2, and -3; and insulin-like factors 3, 4, 5, and 6. In humans, three distinct forms of
relaxin have been identified, of which relaxin-2 is the primary stored form and the only form secreted into the circulation. The biological role of relaxin-1 in humans is still unclear, as is that of relaxin-3, which is found only in the brain. Relaxin-2 has been shown to act as an endocrine and paracrine factor that dilates blood vessels and increases blood flow in tissues (see for review: Dschietzig T et al. in Relaxin: a pregnancy hormone as a central player of body fluid and circulation homeostasis, CMLS 2003; 60:688-700; Dschietzig T et al. in Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics, Pharmacol Ther 2006; 112:38e56).
(003) Numerous clinical applications of relaxin and relaxin agonists and antagonists have been proposed: for the treatment of cutaneous aging, androgenetic alopecia, atrophy, sclerosis, and miniaturization of the hair and hair follicles (EP0793505); for control of fetal growth (EP0991947), for increasing fertility (EP1473034), as an adjuvant in the differentiation of stem cells (EP1696948), for increasing arterial compliance (EP1765149), for diseases related to vasoconstriction (EP1854476), for tumor suppression (WO2007115414), for the treatment of diabetes and related complications (EP1909809), for treating multiple sclerosis and other neurodegenerative dysfunctions (EP2723366), for treating symptoms of aging and neurodegenerative dysfunctions (W00048618), for treating glucotoxicity and impaired glucose tolerance (EP2817026), in treating dyspnea associated with acute heart failure (EP2829280), for treating heart failure with preserved ejection fraction (EP3145534), for treating CNS, CNS trauma, demyelinating disease and/or gliosis, multiple sclerosis (MS), Alzheimer’s disease and Parkinson’s disease, inflammatory conditions of CNS, diffuse cerebral sclerosis of Schilder; acute disseminated encephalomyelitis, acute hemorrhagic leukoencephalitis, transverse myelitis, and neuromyelitis optica, concussion, traumatic brain injury, shaken baby syndrome, traumatic spinal cord injury, traumatic brain injury, ionizing radiation, Korsakoff’s syndrome, multiple systemic atrophy, prion disease, AIDS dementia complex, vasculitis, amyotrophic lateral sclerosis, Huntington’s disease, autoimmune inflammatory disorders, retinal gliosis, encephalopathies, leukodystrophies, encephalitis, neuropathies (EP3347037), for treating various inflammatory conditions, acidic airway hyperreactivity, asthma, rheumatoid arthritis, gout, ankylosing spondylitis, inflammatory enteritis, myositis, systemic lupus erythematosus, sepsis, urticaria, psoriasis, allergic reactions (WO20220374669). However, a particular focus has been the use of relaxin for hemodynamic adaption and regulation of systemic vascular resistance in models of cardiac, renal, pulmonary, and hepatic infarction (WO9303755, W00240500; Dschietzig T et al. in Plasma levels and myocardial expression of relaxin-2 are increased in human heart failure, CIRCULATION 2000, 102(18):594; Coulson CC et al. in Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model, Obstetrics & Gynecology 1996, 87(4):610-612; Masini E. et al. in Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide, Endocrinology 1997, 138:4713-4720; DiLascio G et al. in Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in
a rat model, Tex Heart Inst J 2012, 39:488-499; Collino M et al. in Acute treatment with relaxin protects the kidney against ischemia-reperfusion injury., J Cell Mol Med 2013, 17:1494-1505; Bausys A et al. in Custodiol® supplemented with synthetic human relaxin decreases ischemiareperfusion injury after porcine kidney transplantation, Int J Mol Sci. 2021 , 22, 11417; A/exiou K et al. in Relaxin is a candidate drug for lung preservation: relaxin induced protection of rat lungs from ischemia-reperfusion injury, J Heart Lung Transplant 2010, 29:454-460; Teichmann SL et al. in Relaxin: a review of the biology and potential role in treating heart failure, Curr Heart Fail Rep 2010; 7:75-82). In addition, relaxin has been observed to reduce oxidative cell damages that occur in orthotopic kidney and liver transplants and liver perfusion systems (DE102005040492; Boehnert MU in Relaxin as an additional protective model of isolate perfused rat liver, Ann N Y Acad Sci 2005, 1041 :434-440; Kageyama S et al. in Relaxin in Liver Transplantation: A Personal Perspective Mol Cell Endocrinol. 2019, 487: 75-79; Jakubauskiene L et al. in Relaxin positively influences ischemia-reperfusion injury in solid organ transplantation: a comprehensive review, Int J Mol Sci. 2020, 21 (2):631ff). These findings appear to be consistent with observations that relaxin can act as a ligand of the GR in somatic cells, completely independent of the signaling cascades of the G-protein-coupled relaxin receptors RXFP1 and RXFP2 (formerly designated LGR7 and LGR8, respectively). Experiments in Hela cells have confirmed this, HEK cells and Th1 -activated macrophages showing that relaxin-2 activates GR and that the relaxin-GR complex depresses stimulated secretion of the cytokines IL-1 , IL-6, and TNF-a like dexamethasone (Dschietzig TB et al. in Identification of the pregnancy hormone relaxin as a glucocorticoid receptor agonist, FASEB J 2004, 18:1536-1538; Dschietzig T et al. in The pregnancy hormone relaxin binds to and activates the human glucocorticoid receptor, Ann N Y Acad Sci. 2005, 1041 :256-71 ; Dschietzig T et al. in RXFP1 -inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway, Regul Pept. 2009, 154:77-84; Dschietzig T et al. in Autoregulation of human relaxin-2 gene expression critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter, Regul Pept. 2009, 155:163-73). The presence of relaxin also stimulates gene expression in the NOTCH 1 intracellular domain (NICD), and the associated intercellular signaling appears to result in a diminished ischemia-reperfusion injury. However, ischemia-reperfusion injury (IRI) is an inevitable consequence of many clinical conditions, including trauma, sepsis, resection, and transplantation, and an immune-driven inflammatory response leading to cell death and early graft dysfunction. Liver biopsies in humans nevertheless suggest that the high NICD expression enhances resistance to IRI. The use of relaxin in organ preservation solutions for donor kidneys and livers appears promising to improve IRI resistance. On the other hand, their side effects limit the clinical use of glucocorticoids and GR-ligands.
(004) Because almost all cells in the body express the same glucocorticoid receptor, the pharmacologically highly desirable effects of glucocorticoids and GR activation are equally associated with specific adverse effects caused thereby. Adverse metabolic and
pharmacologic effects of prolonged glucocorticoid treatment include wound healing disorders, manifestation/deregulation of diabetes mellitus, adverse immunosuppression, increased risk of infection, osteoporosis, growth disturbances in children as well as myopathy/muscular atrophy, skin atrophy, steroid acne, hirsutism in addition to the typical symptoms of a Cushing’s syndrome such as uncontrollable hypertension, disturbances of salt and water balance, psychological and neurological disorders, depression, etc. Therefore, an individual benefit-risk analysis must be performed for each glucocorticoid therapy, primarily when treating cancer patients and transplant patients who receive such hormone therapy. This applies to patients suffering from a hormone-refractory type of tumor who are to be treated by a combination of a specific antibody and steroids to inhibit the proliferation of cancer cells. This is particularly true for patients who have a chronic inflammatory disease but for whom the harmful side effects of prolonged glucocorticoid treatment would outweigh the painful or debilitating effects of the underlying disease. The known prior art provides no guidance as to whether and when treatment with relaxin is medically justified. The prior art in this field, therefore, represents a problem.
SUMMARY OF THE INVENTION
(005) The problem is solved by a pharmaceutical composition for treating a patient in need of a therapy dampening physiologic inflammatory reactions by the innate immune system, comprising an effective amount of synthetic human relaxin-2 and a pharmacological solvent, diluent, or excipient.
(006) In some embodiments, the patient suspected of requiring a dampening of physiologic inflammatory reactions by the innate immune system is tested for one or more of the following serum parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greater than or equal to 0.5 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, or serum calprotectin greater than or equal to 10 micrograms/ml.
(007) The problem is further solved by a pharmaceutical composition for treating a patient suffering from inflammatory responses triggered by the innate immune system and/or requiring suppression through a ligand-activated glucocorticoid receptor, which comprises as an active ingredient an effective amount of synthetic human relaxin-2 and a pharmacological solvent, diluent, or excipient, whereby manifestation or deregulation of diabetes or the symptoms of a Cushing’s syndrome are avoided.
(008) In some embodiments, the patient suspected of having inflammatory responses triggered by the innate immune system has the following clinical criteria: prediabetes (HbA1 C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher according to the 2017 ACC/AHA Guidelines).
(009) In some embodiments, the pharmaceutical composition comprising an effective amount of synthetic human relaxin-2 is for treating a patient in need of an altered body or organ development while also preventing manifestation or deregulation of diabetes or symptoms of a Cushing’s syndrome. Said patient may already display have the following clinical characteristics: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher).
(010) In some embodiments, the pharmaceutical composition comprising an effective amount of synthetic human relaxin-2 is for treating a patient having received an allotransplant and in need of a dampening of the innate immune system and inflammatory responses while preventing compromised wound healing, manifestation, or deregulation of diabetes or symptoms of a Cushing’s syndrome. Said medical need of a dampening of the innate immune system is given in case of a transplant patient when one or more of the following four criteria are fulfilled: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml.
(011) In some preferred embodiments, the pharmaceutical composition comprising an effective amount of synthetic human relaxin-2 is for treating a patient in need of chronic suppression of the innate immune system and inflammatory responses while preventing manifestation or deregulation of diabetes or symptoms of a Cushing’s syndrome.
(012) In some embodiments, said patient suspected of requiring a chronic suppression of inflammatory reactions manifests one or more medical criteria selected from serum HMGB1 (high-mobility group box protein) greaterthan or equal to 4 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greaterthan or equal to 0.5 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml.
(013) In some other embodiments, said pharmaceutical composition is for treating a patient in need of hormone-refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy through a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers; Kaposi Sarcoma, the synthetic human relaxin-2 being used as supplement and substitute of the glucocorticoid receptor activating hormone.
(014) Another aspect of the invention relates to a method of treating a patient which comprises testing said patient for one or more of the following clinical parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greaterthan or equal to 0.5 ng/ml; serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml, and when given, administering to the
patent an effective amount of synthetic human relaxin-2 within a pharmacological solvent, diluent, or excipient to dampen or suppress physiologic inflammatory reactions by the innate immune system.
(015) In some embodiments, said method steps are used for treating a patient suffering from inflammatory responses triggered by the innate immune system and/or requiring suppression through a ligand-activated glucocorticoid receptor, wherein the active pharmacological ingredient is synthetic human relaxin-2 to avoid a manifestation or deregulation of diabetes or the symptoms of a Cushing’s syndrome.
(016) In some other embodiments, said method of treatment comprises administering an effective amount of synthetic human relaxin-2 a patient in need of an altered body or organ development while preventing manifestation or deregulation of diabetes or symptoms of a Cushing’s syndrome.
(017) In some embodiments, the method comprises administering an effective amount of synthetic human relaxin-2 to a patient who has received an allograft and requires suppression of innate immune and inflammatory responses without compromising wound healing, manifesting or deregulating diabetes, or inducing symptoms of a Cushing’s syndrome, after testing the transplant patient positive on one or more of the following medical criteria: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml.
(018) In some other embodiments, the method of treatment comprises administering an effective amount of synthetic human relaxin-2 to a patient diagnosed as needing hormone- refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy by a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers, Kaposi’s sarcoma, wherein the synthetic human relaxin-2 is used to supplement and/or replace glucocorticoid receptoractivating hormone. Alternatively, in some embodiments, the method comprises administering an effective amount of synthetic human relaxin-2 to a patient who requires an extra or substitute for a glucocorticoid receptor activating hormone.
(019) In some embodiments, the method of treatment comprises administering an effective amount of synthetic human relaxin-2 to a patient diagnosed as needing immunosuppressive therapy, wherein the synthetic relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone to prevent or avoid a manifestation or deregulation of diabetes or symptoms of Cushing’s syndrome, mainly when the patient displays one or more of the following clinical features: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (Level 1 or higher according to the 2017 ACC/AHA guidelines).
(020) In some embodiments of the method of treatment, the patient is initially diagnosed as requiring chronic doses of corticosteroids and/or glucocorticoids and it comprises subcutaneously administering an appropriate amount of synthetic human relaxin-2 thereby avoiding a manifestation or deregulation of diabetes, wound healing disorders, or the symptoms of Cushing’s syndrome.
(021) In some embodiments of the method of treatment described above, the patient suffers from forms of autoimmune or rheumatic diseases; ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA) and inflammatory types of arthritis, rheumatoid arthritis (RA).
(022) In some embodiments of the method of treatment described above, the method comprises testing the patient for one or more of the following clinical parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greater than or equal to 0.5 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml, and when given, administering to the patent an effective amount of synthetic human relaxin-2 within a pharmacological solvent, diluent, or excipient to dampen or suppress physiologic inflammatory reactions by the innate immune system.
(023) In some embodiments of the method of treatment described above, the method comprises treating a patient suffering from SIRS (systemic inflammatory response syndrome), autoimmune or rheumatic diseases, thyroiditis, gastritis, insulitis, sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, polyarthritis, ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA) and inflammatory types of arthritis, rheumatoid arthritis (RA), SARS-Covid 19 und SARS.
(024) In some embodiments of the method of treatment described above, the method comprises treating a patient suffering from immunological reactions by the innate immune system and/or displays the following clinical criteria: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher according to the 2017 ACC/AHA Guidelines).
(025) In some embodiments of the method of treatment described above, the method comprises treating a patient suffering from inflammatory responses triggered by the innate immune system and/or requires suppression of inflammatory responses through a ligand- activated glucocorticoid receptor, wherein the active pharmacological ingredient is synthetic human relaxin-2 to avoid a manifestation or deregulation of diabetes, wound-healing disturbance, and/or the symptoms of Cushing’s syndrome.
(026) In some embodiments of the method of treatment described above, the method comprises treating a patient who has received an allograft and requires suppression of the innate immune system and inflammatory responses, after testing the patient positive on one or more of the following medical criteria: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml.
(027) In some embodiments of the method of treatment described above, the method comprises treating a patient who is in need of hormone-refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy by a ligand- activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers, Kaposi’s sarcoma, wherein synthetic human relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone.
(028) In some embodiments of the method of treatment described above, the method comprises treating a patient diagnosed as requiring immunosuppressive therapy, wherein synthetic relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone to prevent or avoid a manifestation or deregulation of diabetes or symptoms of Cushing’s syndrome, particularly when the patient displays one or more of the following clinical features: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (Level 1 or higher according to the 2017 ACC/AHA guidelines).
(029) Further aspects and advantages of embodiments of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, illustrated by way of example of the principles of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
(030) In the figures and drawings appended hereto: -
Fig. 1 is a diagram showing a microscale thermophoresis of the high-affinity binding (KD ~ 5 nM) of H2 relaxin to helix 12 of the ligand-binding domain of the human GC receptor in the absence of the co-activator TIF2.
Fig. 2 is a diagram of a microscale thermophoresis showing the lower affinity interaction (KD ~500 nM) of H2 relaxin to the ligand-binding domain of the human GC receptor.
Fig. 3 is a data plot of the release of lactate dehydrogenase (LDH) from cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury); induction by H2O2; induction by H2O2 after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); after knockdown of the GC receptor by added siRNA (GRsi) and scrambled siRNA (scr) as a control - all data in percent of detergent-induced maximal cytotoxicity.
Fig. 4 is a data plot of the release of cleaved caspase-3 from cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury); cell injury by H2O2; after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); after knockdown of the GC receptor by addition of siRNA (GRsi) and scrambled siRNA (scr) as a control - all data normalized to p-actin and adjusted to the effect of H2O2.
Fig. 5 is a data plot comparing the relative amounts of cytosolic GC receptor (GR) in cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury), by addition of H2O2; after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); relaxin-2 or dexamethasone alone - all data normalized to control.
Fig. 6 is a data plot comparing the relative amounts of mitochondrial pyruvate dehydrogenase lipoamide kinase isoenzyme 4 (PDK-4) in cultured primary mouse hepatocytes after induced cell injury: Control (no cell injury), cell injury by addition of H2O2; cell injury after treatment of cells with relaxin-2 (Rix) or dexamethasone (Dx); added relaxin-2 or dexamethasone alone - all data normalized to control.
Fig. 7 is a data plot comparing concentrations of tumor necrose factor-alpha (pg/mL) - an adipokine and cytokine - in the supernatants of activated Th1-macrophages: Control (no activation); activation by lipopolysaccharides (endotoxin); after treatment of macrophages with relaxin-2 (Rix) or dexamethasone (Dx) or Mifepristone-RU486 (RU) or LPS+Rlx+RU486 or LPS+Dx+RU486.
Fig. 8 is a data plot comparing concentrations of interleukin-6 (pg/mL) - pro-inflammatory cytokine - in the supernatants of activated Th1-macrophages: Control (no activation); activation by lipopolysaccharides (endotoxin); after treatment of macrophages with relaxin-2 (Rix) or dexamethasone (Dx) or Mifepristone-RU486 (RU) or LPS+RIX+RU486 or LPS+Dx+RU486.
Fig. 9 is a data plot comparing concentrations of circulating tumor necrose factor alpha (pg/mL) in blood from rats 24 hours after challenge with E. coli endotoxin: Control (placebo - no endotoxin); challenge with E.coli endotoxin (125 pg LPS I kg body weight); 2 hours after continuous sc. infusion (4 pg/h) of synthetic relaxin-2 (Relaxera Pharmazeutische GmbH, DE); i.m. injection of dexamethasone (10 mg/kg); oral RU- 486 (single dose of 10 mg /kg body weight) or combinations thereof;
Fig. 10 is a data plot comparing concentrations of fasting blood sugar levels (24 hours) in rats after exposure to E. coli endotoxin: control (placebo - no endotoxin); challenge with E. coli endotoxin (125 pg LPS I kg body weight); challenge 2 hours after continuous subcutaneous infusion (4 pg/h) of synthetic relaxin-2 (Relaxera Pharmazeutische GmbH, Bensheim, DE); intramuscular injection of dexamethasone (10 mg/kg im.; oral RU-486 (single dose of 10 mg /kg body weight) or combinations thereof.
Fig. 11 is a data plot comparing concentrations of fasting blood sugar levels (48 hours) in blood
from rats after challenge with E. coli endotoxin: Control (placebo - no endotoxin); challenge with E. coli endotoxin (125 pg LPS I kg body weight); challenge 2 hours after continuous sc. infusion (4 pg/h) of synthetic relaxin-2 (Relaxera, Bensheim, DE); intramuscular injection of dexamethasone (10 mg/kg); oral RU-486 (single dose of 10 mg /kg body weight) or combinations thereof.
Fig. 12 is a data plot comparing the percentage of T reg macrophages (CD4+CD25+ regulatory T cells) in blood from rats after continuous sc. infusion (4 pg/h) of relaxin-2 or oral RU- 486 (single dose of 10 mg /kg body weight) or both - all data as a percentage of the total white blood cell count (WBC).
(031 ) In Figures 3 to 12, the boxes indicate the interquartile range, with the inner line representing the median; the whiskers indicate 1 ,5-times the interquartile range; values above 1 .5 times (outliers) and 3 times the interquartile range (extreme range) are shown as circles and stars, respectively.
DETAILED DESCRIPTION OF THE INVENTION
(032) Millions of patients take glucocorticoids to treat autoimmune and rheumatoid diseases, neurological disorders, pulmonary diseases, cancer, and other diseases and causes. However, the chronic side effects of glucocorticoids and their adverse consequences are much feared, particularly the negative impact due to glucocorticoid receptor (GR) down-regulation, steroid-induced hyperglycemia, or activation of gluconeogenesis as well as Cushing’s syndrome. The present inventors have discovered that relaxin-2 binds the ligand-binding domain of the GR like steroids and glucocorticoids, forming an activated GR-ligand complex. The relaxin-GR complex activates the transcription of genes dampening the innate immune system but no genes activating gluconeogenesis, unlike the glucocorticoids or corticosteroids. This discovery enlarges the therapeutic applications of relaxin-2 for patients in need of a dampened innate immune system. This group of patients comprises for example patients who receive or have received an allotransplant, and cancer patients. Another large group are patients suffering from forms of tissue/endothelial injury or tissue-damaging diseases, including autoimmune or rheumatic tissue-damaging diseases comprising ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA), and inflammatory types of arthritis, rheumatoid arthritis (RA). Medications for these diseases include corticosteroids, oral and topical analgesics, non-steroidal anti-inflammatory drugs such as ibuprofen and COX-2 inhibitors, and disease-specific biologies. Tissue injury, endothelial injury, and endothelial cell activation, particularly in allograft rejection, can be detected and monitored by increased concentrations of calprotectin and/or S100A12 in extracellular fluids and the bloodstream. This
is because endothelial cells also play a critical role in immune cell recruitment and extravasation. The calcium-binding S100 proteins, particularly calprotectin and S100A12, have a wide range of intracellular and extracellular functions, including regulation of calcium balance, cell apoptosis, cell migration, differentiation, proliferation, energy metabolism, and inflammation. The calcium-binding S100 proteins are released from the cytoplasm of the endothelial cell when triggered by tissue/cell damage, antibody stress, and endothelial stress. The S100 proteins then serve as danger signals, DAMP (damage-associated molecular pattern) molecules, and are involved in the regulation of immune homeostasis (macrophage migration, invasion, and differentiation), post-traumatic injury, and inflammation. They are therefore biomarkers in some specific diseases such as IBD (inflammatory bowel disease), although their multiple functions must be assigned to cell migration, differentiation, tissue repair, immune homeostasis, and inflammation management. The lack of commonly available diagnostic tests for tissue injury, endothelial injury, endothelial stress, and anti-endothelial cell antibody binding, which undoubtedly lead to allograft dysfunction and allograft rejection, makes calcium-binding S100A12 and calprotectin biomarkers for endothelial activation, immune cell recruitment, endothelial injury, endothelial antibody binding, and complement activation.
(033) Furthermore, the present inventors discovered that relaxin-2 not only binds to the glucocorticoid receptor as shown in Fig. 1 but that the experimental results in Fig. 12 further indicate that the administration of relaxin-2 leads to a specific activation and promotion of regulatory T cells at local and systemic levels, likely induced by the relaxin-GR complex. This allows suppression of immune responses and significantly widens the use of relaxin-2 as an active ingredient in pharmaceuticals for treating abnormal, excessive, and undesired tissuedamaging immune responses to self- and foreign antigens. While the promotion of peripherally induced Treg cells could also be achieved by the administration of glucocorticoids, such treatment is disadvantageous due to the Cushingoid adverse effects of glucocorticoids, corticosteroids, and synthetic analogs thereof. Their adverse effects are well-known and numerous (cf. 2022 ICD-10CM Code T38.0X5A).
(034) Regulatory T cells (Treg cells) were originally defined as CD4+ T cells with a high expression of CD25 (interleukin-2 receptor a-chain). The regulatory T cells are further classified into thymic and peripherally induced Treg cells based on where they develop. The Foxp3 gene, a member of the Forkhead/winged-helix family of transcriptional regulators, was discovered to be an important regulator in the development of Treg cells based on the following findings: Scurfy mice with a frameshift mutation in the Foxp3 gene have T cell inflammation in multiple organs and a lethal autoimmune disease due to effector T cell activation and increased cytokine production caused by the absence of Treg cells. In addition, mutation of the Foxp3 gene in humans leads to IPEX syndrome (X-linked immune dysregulation, polyendocrinopathy, and enteropathy). In addition, forced expression of FoxP3 in naive T cells leads to immune suppressive function. CD4/CD25-naive T cells transfected with the Foxp3 gene can transform into CD4+CD25+ Treg-like cells that produce inhibitory cytokines and express typical Treg-cell
molecules such as CD25, cytotoxic T-lymphocyte antigen-4 (CTLA-4), and glucocorticoid- induced tumor necrosis factor (TN F) receptor-related protein (GITR). Thus, FoxP3 is a lineagespecific marker and an important regulatory gene for the generation, maintenance, and immune suppressive functions of Treg cells. Regulatory T cells are required to suppress abnormal or excessive immune responses and to maintain homeostasis and self-tolerance by inhibiting T cell proliferation and cytokine production. The Treg cells exert their immunosuppressive function through dominant consumption of the cytokine interleukin-2 and by inhibitory cytokines (TGF-B, IL-10, IL-35) as well as induction of apoptosis or a killing of effector or antigen-presenting cells (APC) by perforin, granzyme B or Fas ligand interaction. The other immunosuppressive mechanisms of Treg cells involve immune checkpoint molecules and include inhibition of effector T cells by the lymphocyte activation programmed cell death pathways or the cytotoxic T-lymphocyte antigen (CTLA-4). A third immunosuppressive mechanism may be metabolic modulation by indoleamine 2,3- dioxygenase (IDO) expression, which affects the kynurenine-tryptophan pathway in dendritic cells. The Treg cells thereby play a critical role in suppressing autoimmunity and inflammation. Reduced number and function of Treg cells are associated with human autoimmune disease, and activation and augmentation of Treg cells have been shown to be beneficial in treating autoimmune diseases in clinical trials (see the review of Margarita Dominquez-Vallar & David A. Hafler, Regulatory T cells in autoimmune disease, Nature Immunology 2018, 19, 665-673). Overall, all current results suggest that Treg cells contribute to the maintenance of selftolerance by downregulating the immune response to self and foreign antigens in an antigen- nonspecific manner. Therefore, it is reasonable to hypothesize that a relaxin-2-induced increase in Treg cells in a posttransplant patient also improves post-transplant outcomes beyond the prevention of ischemic injury. The very same can also be assumed when relaxin- 2 is used in treating autoimmune induced tissue injury, endothelial cell injury and diseases following endothelial cell activation. The hypothesis is also supported by the fact that a reduction in the proportion of Treg cells in the peripheral blood is known to lift general immune suppression, thereby enhancing the innate and acquired immune response to foreign and selfantigens. Therefore, the present discovery significantly expands the pharmaceutical toolbox.
EXAMPLES
EXAMPLE 1 - Relaxin binds and activates the glucocorticoid receptor
(035) Fig .1 and Fig. 2 refer to in vitro binding and affinity studies of synthetic human relaxin-2 (shRIx) to the ligand-binding domain of the glucocorticoid receptor (GR-LBD) using microscale thermophoresis (MST). The microscale thermophoresis is based on measuring the directed movement of molecules in localized temperature gradients created by IR laser
radiation in high-precision glass capillary tubes containing the interacting partners - synthetic human relaxin-2 and recombinant GR-LBD. For this experiment, the human glucocorticoid receptor (GR-LBD) ligand-binding domain was expressed in an E. coli expression system to obtain a large amount of soluble protein stable for biophysical characterization. The recombinantly produced GR-LBD showed little aggregation and proved to be fully functional. One of the interacting partners was labeled with a fluorescent dye and added to a serial dilution series (15 dilutions each) of the non-fluorescent partner. After incubation, the thermophoretic movement of the complex is detected. Conformational changes due to ligand binding to the target or binding near the fluorophore induce thermophoretic changes. The affinity of interacting protein is determined by analyzing the change in normalized fluorescence as a function of the concentration of titrated binding partner. The next step was to determine the binding mode of relaxin and the activation mechanism of GR. Fluorescence polarisation revealed two binding affinities in the pico- and nanomolar range. Moreover, human H2 relaxin could displace fluormone labeled GS red out of its binding pocket on GR-LBD (see method described by Hemmerling M et al. in Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases, J. Med. Chem. 2017, 60, 20, 8591-8605). Using this combination of biophysical and structural biology techniques, including microscale thermophoresis (MST), hydrogen-deuterium exchange mass spectrometry (HDX- MS), and NMR, the relaxin-2 binding site of the glucocorticoid receptor was identified, which was the steroid-binding pocket of the GR-LBD.
(036) The effects of relaxin binding on GR-LBD have further been investigated to determine whether relaxin binding activates the receptor like an agonist or represses transcriptional activity by acting like an antagonist. GR-LBD has an activation function-2 site that will recruit cofactors upon ligand binding. The cofactors (coactivators or corepressors) are specific to the cellular environment. Therefore, the binding of relaxin with coactivator and corepressor motifs to the GR-LBD/relaxin complex was tested.
(037) It was found that relaxin binds to both cofactors, resulting in different receptor conformational changes. Since thermophoresis is an intrinsic phenomenon of a molecule that depends on the hydration shell and the size, the binding events could be identified by tracking the associated changes to thermophoresis in a fluorescently labeled interacting partner. In summary, the results of the microscale thermophoresis (see Figs. 1 , and 2) indicate a high- affinity interaction (KD ~ 5 nM) and another lower-affinity interaction (KD ~ 500 nM) of synthetic human relaxin-2 with the GR-LBD.
(038) According to hydrogen-deuterium exchange experiments (not shown), human relaxin-2 appears to bind to helix 12 of the LBD, but in contrast to classical glucocorticoids in the absence of the transcription co-regulator NCoA-2 (nuclear receptor coactivator 2). NCoA-
2 is also known as glucocorticoid receptor-interacting protein 1 (GRIP1), steroid receptor coactivator-2 (SRC-2), or transcription intermediary factor 2 (TIF2). NCoA-2 contains several
nuclear receptor interacting domains and intrinsic histone acetyltransferase activities, and when GR recruits NCoA-2 to a DNA promotion site, the role of NCoA-2 also appears to be in acetylating histones so that the downstream DNA becomes more accessible for transcription. The presence and amount of NCoA-2 are cell-type dependent. NCoA2 (GRIP1 , SRC-2, TIF2) therefore supports up-regulation of DNA expression which also leads to increased activation of genes responsible for gluconeogenesis. Since human relaxin-2 does not recruit NCoA-2 upon binding, this type of gene activation does not appear to be triggered when human relaxin- 2 binds to the glucocorticoid receptor.
EXAMPLE 2 - Relaxin-2 activates transcription of genes dampening peroxide-induced cytotoxicity, inflammatory responses, and apoptosis
(039) With reference to Fig. 3 and Fig. 4, mouse hepatocytes were isolated as described by Tamaki N et al. in Am J Physiol Gastrointest Liver Physiol 2008 294, G499. Briefly, livers from mice anesthetized with pentobarbital were washed and perfused for 5 min with buffer consisting of (all values are mg/L) 8,000 NaCI, 400 KCI, 88,7 NaH2PO4 H2O, 120.45 Na2HPO4, 2,380 HEPES, 350 NaHCO3, 190 EGTA, and 900 glucose, pH 7.25, then treated with 0.03% collagenase at 37°C for 15 min in digestion buffer containing (all values are mg/L) 8,000 NaCI, 400 KCI, 88.7 NaH2PO4 H20, 120.45 Na2HPO4, 2,380 HEPES, 350 NaHCO3, and 560 CaCl2'2H2O , pH 7.25. After collagenase perfusion, the liver capsule was isolated, and the cells dispersed in Geys balanced salt solution (GBSS)-B consisting of (all values in mg/L) 8,000 NaCI, 370 KCI, 210 MgCI2'6H2O, 70 MgSO4-7H2O, 120 NaH2PO4, 30 KH2PO4, 991 glucose, 227 NaHCO3, and 225 CaCl2'2H2O (pH 7.25). Cells were additionally separated by forcing the material through a steel mesh and collecting the cells by centrifugation at 50 G for 1 min. The cell pellet was resuspended in GBSS-B solution and washed three times with intermittent centrifugations.
(040) Isolated mouse hepatocytes were cultured on type I collagen-coated 6-well plates coated at a cell density of 5 x 105 cells/well with Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 U/ml penicillin, and 100 pg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2-95% air. After plating, the medium was replaced with serum- free Dulbecco's modified Eagle medium after 6 hours. The hepatocytes were then subjected to hydrogen peroxide treatment (2 mM H2O2/L) for 5 hours with or without pretreatment with synthetic human relaxin-2 (10 nM/L, 24 h) (Relaxera Pharmazeutische GmbH, Bensheim, DE) or dexamethasone (0,5 mM, 24 h) (Sigma Aldrich). In addition, hepatocytes were also transfected with GR-siRNA or scrambled siRNA using lipofectamine reagent (Invitrogen) to test whether the release of LDH or caspase-3 into the medium in these two experiments was dependent on the ligand-activated GR reagent (n = 5 for each group). H2O2-induced cell injury (cytotoxicity) was determined immunologically by quantification of lactate dehydrogenase (LDH) released into the culture medium using an enzyme-linked assay according to the
manufacturer’s instructions (Goat LDH ELISA kit, Biomol Feinchemikalien GmbH, DE) and by Western Blot analysis of cleaved caspase-3 (Caspase-3 Rabbit mAb #14220, Cell Signaling Technology, Danvers, MA, US).
(041) The results are summarized in Figs. 3 and 4. LDH release data shown in Fig. 3 are expressed as a percentage of detergent-induced maximum cytotoxicity. Data on cleaved/activated caspase-3 shown in Fig. 4 were normalized to p-actin and adjusted for the effect of H2O2 (* p < 0.05 vs. control; #, p < 0.05 vs. H2O2; Kruskal-Wallis ANOVA on ranks for global testing with post hoc Mann-Whitney U-tests for pairwise comparisons (Bonferroni-Holm adjustment of p). In summary, Figs. 3 and 4 show that both relaxin-2 (Rix) and dexamethasone (Dx) can markedly dampen peroxide-induced cell injury (LDH release) and apoptosis (cleaved caspase-3) and that this attenuating effect does not occur when the expression of GR is specifically knocked out by GR-siRNA, whereas a knock-out using scrambled siRNA (scr- siRNA) showed no effect.
(042) Physiologically, LDH is an enzyme expressed in nearly all living cells, including heart muscles and blood cells, and it catalyzes the conversion of lactate to pyruvate and back. Because it is released during tissue injury, it is a marker of common injuries, damaged tissues, and diseases involving tissue damage such as heart failure. In contrast, the relative concentrations of its substrates primarily regulate LDH activity. LDH is subject to transcriptional regulation by peroxisome proliferator-activated receptor-y coactivator 1a (PGC-1a) in an estrogen-related receptor-a-dependent manner.
(043) Caspase 3 protein (CASP3) or cysteine-dependent aspartate-directed protease 3 plays an essential role in programmed cell death. Caspase-3 is synthesized as an inactive zymogen until cleaved after apoptotic signaling events. Caspase-3 is thought to ensure that cellular components are degraded in a controlled manner, and that cell death occurs with minimal impact on surrounding tissues. Caspase deficiency has been identified as a cause of tumor development, for example, by a mutation in a cell cycle gene that removes cell growth restrictions in combination with mutations in apoptotic proteins such as caspases that would trigger cell death in abnormally growing cells. Conversely, over-activation of caspase-3 can lead to excessive programmed cell death. This is seen in several neurodegenerative diseases in which neural cells are lost, such as Alzheimer's disease. Caspases involved in processing inflammatory signals are also implicated in disease. Insufficient caspase activation can increase an organism's susceptibility to infection because an appropriate immune response may not be triggered. For example, inflammatory caspase-1 has been linked to the development of autoimmune diseases; drugs that block caspase activation have been used to improve patients’ health.
(044) In conclusion, synthetic relaxin-2 as a ligand of the glucocorticoid receptor appears to have cell biological effects like dexamethasone in attenuating an inflammatory response to tissue injury as well as apoptosis and necrosis.
EXAMPLE 3 - Relaxin-GR complex does not activate transcription of genes involved in gluconeogenesis
(045) Mouse hepatocytes were obtained and tested for glucocorticoid-adverse effects after treatment with synthetic human relaxin-2 or dexamethasone (500 nM, 24 hours). The complex physiological adverse effects of glucocorticoid excess are numerous and difficult to assess (Cushing’s syndrome, diabetes, skin thinning, hypertension, osteoporosis, obesity, impaired wound healing, depression, etc.), but measurable in this cell assay is the activation of genes involved in gluconeogenesis and in diabetes, obesity, and impaired wound healing. Consequently, the regulation of GR- and PDK-4 transcription was examined by qRT-PCR in normal primary mouse hepatocytes for control and in H2O2-stressed primary mouse hepatocytes from example 2 after 24 hours of treatment with 10 nM/L synthetic human relaxin- 2 (Relaxera Pharma. GmbH&Co.KG) and 500nM/L dexamethasone (Sigma Aldrich). Results are shown in the block diagrams of Figs. 5 and 6.
(046) Specifically, Fig. 5 shows that relaxin-2 increases GR gene transcription in normal and H2O2-stressed primary mouse hepatocytes by 100% to 200 %, whereas dexamethasone has no such effect. Fig. 6 shows that the incubation with relaxin-2 has no effect on PDK-4 gene transcription in normal and H2O2-stressed primary mouse hepatocytes. However, when primary mouse hepatocytes are incubated with dexamethasone, PDK-4 gene transcription increases severalfold. The combination of Figs. 5 and 6 is therefore strong evidence that the complex of relaxin and GR binds to a genomic DNA locus that is different from the DNA locus of steroid-activated GR.
(047) Physiologically, PDK-4 (pyruvate dehydrogenase lipoamide kinase isozyme 4) is a mitochondrial protein that inhibits the pyruvate dehydrogenase complex (PDH) by phosphorylating one of its subunits. An active PDH complex is required to convert pyruvate to acetyl-CoA for the glycolytic products to enter the citric acid cycle. Fasting results in an induction of PDK-4 mRNA and PDK-4 enzyme in both cardiac and skeletal muscle, suppressing glucose oxidation during starvation as part of an integrative response and for glucose maintenance. The PDK-4 enzyme is therefore thought to play a critical role in regulating glucose metabolism, whereas an increased PDK-4 transcription indicates gluconeogenesis. It is well known that PDK-4 expression is physiologically regulated by glucocorticoids, retinoic acid, and insulin which enhance the transcription of the PDK-4 gene in white adipose tissue. Oxidation of fatty acids is also increased when the PDK-4 level is elevated. Insulin downregulates PDK-4 mRNA transcription. When cells are exposed to dexamethasone to increase PDK-4 mRNA expression, insulin blocks this effect and the oxidation of fatty acids. In type 2 diabetes, PDK-4 is overexpressed in skeletal muscle, resulting in impaired glucose utilization. In patients suffering from obesity, PDK-4 mRNA expression is also markedly decreased in association with increased glucose uptake, likely due to the downregulation of PDK-4 by insulin. This is consistent with the hypothesis that fatty acid
availability affects glucose metabolism by regulating the pyruvate dehydrogenase (PDH) complex. Indeed, in insulin-resistant individuals, an inadequate downregulation of PDK-4 mRNA may cause increased PDK-4 expression, leading to impaired glucose oxidation followed by increased fatty acid oxidation. Conversely, PDK-4 is downregulated in cardiac muscle tissue during heart failure, which is a physiological countermeasure (Razeghi P et al., in Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading, Cardiology 2002, 97(4):203-9).
(048) The results in Figs. 3 through 6 show that relaxin-2 like glucocorticoids, corticosteroids, and mineralocorticoids has anti-inflammatory effects, but without leading to impaired glucose oxidation, increased fatty acid oxidation, and gluconeogenesis. The ubiquitous role of PDK-4 further suggests that a pharmaceutical composition containing relaxin-2 and treatment with relaxin-2 may be an alternative to glucocorticoid treatment because it results in increased expression of the glucocorticoid receptor, which suppresses immune and inflammatory responses, but not in increased expression of PDK-4, which is unfavorable for glucose metabolism and balance.
(049) The glucocorticoid receptor (GR) is an evolutionarily conserved liganddependent transcription factor. Upon binding of a steroid hormone or other ligand, the receptor migrates from the cytoplasm to the nucleus where it binds to a genomic DNA locus and positively or negatively modulates the transcription rates of the locus-associated genes. Tremendous efforts have been made to uncover the molecular signaling actions of the GR, including intracellular shuttling, transcriptional regulation, and interaction with other intracellular signaling pathways. In brief, glucocorticoids are essential for the maintenance of resting-state and stress response and, therefore, they are essential in the treatment of numerous diseases, including autoimmune, inflammatory, allergic, and lymphoproliferative disorders. The pathological or therapeutic implications of the GR cannot be overstated. These include, except for genetic alterations in the human GR gene, disease-associated GR regulatory molecules and the development of GR ligands with selective GR action.
(050) Figs. 1 to 6 show that the administration of synthetic relaxin-2 has therapeutic effects that differ from known corticosteroids and glucocorticoids. The experiments presented demonstrate that synthetic relaxin-2 elicits GR-dependent glucocorticoid effects, including inhibition of apoptosis in mouse hepatocytes and inhibition of cytokine release in human macrophages (see example 4 below), which, in contrast to classical corticosteroids and glucocorticoids, avoid unwanted effects such as GR down-regulation or glucocorticoid- or steroid-induced hyperglycemia or activation of gluconeogenesis.
EXAMPLE 4 - Relaxin-2 dampens the release of pro-inflammatory cytokines
(051) THP-1 cells were differentiated into macrophages and cultured as described by Dschietzig T et al. in Identification of the pregnancy hormone relaxin as a glucocorticoid receptor agonist, FASEB J 2004, 18:1536-1538. Briefly, the THP-1 cells are derived from a cell line generated from a human monocyte leukemia, and when the cells are treated in the passage with myristate-phorbol ester, they differentiate into macrophages as is well known in the art.
(052) Referring to Figs. 7 and 8, the macrophages were then challenged for 24 hours with 10 ng/ml Salmonella abortus equii endotoxin (Sigma Aldrich) in the presence or absence of synthetic human relaxin-2 (10 nM/L) and dexamethasone (500 nM(L) and/or the GR antagonist RU-486 (500 nM) (Sigma Aldrich), or combinations thereof (n = 5 for each group). RU-486 binds to the GR in the steroid pocket of the ligand-binding domain. Subsequently, the supernatant levels of TNF-a and interleukin-6 were determined by ELISA (R&D Systems).
(053) The results are summarized in the block diagrams for Figs. 7 + 8, and demonstrate that the endotoxin induced these macrophages to produce and excrete the proinflammatory cytokines tumor necrose factor alpha (TNF) and interleukin-6 (IL-6), which inflammatory response was both depressed in the presence of synthetic human relaxin-2 and dexamethasone. This response can be classified as GR-dependent, as RU-486 completely inhibited this effect.
(054) As further background, RU-486, also known as Mifepristone®, is a steroidal antiprogesterone as well as an antiglucocorticoid and antiandrogen. It competitively antagonizes cortisol action at the GR receptor. In humans, an antiglucocorticoid effect of RU- 486 is observed at doses greater or equal to 4.5 mg/kg through a compensatory increase in adrenocorticotropic hormone (ACTH) and cortisol. In animals, a weak antiandrogenic effect is seen with prolonged administration of very high doses (Danco Laboratories, 2005, Mifeprex U.S. prescribing information). Thus, this example demonstrates that the administration of synthetic human relaxin-2 can provide GR-mediated regulation of the immune system, and has immune-suppressive properties, but without the side effects of inducing gluconeogenesis and insulin insensitivity.
EXAMPLE 5 - Relaxin-GR complex does not induce hyperglycemia in contrast to the dexamethasone-GR complex
(055) Figs. 9, 10, and 11 refer to animal experiments and show the different effects of relaxin-2 and dexamethasone (Sigma Aldrich) administration on blood glucose levels in rats after 24 and 48 hours. In brief, male and female Sprague-Dawley rats (body weight 300 - 350 g) were treated with an intraperitoneal injection of E coli endotoxin (125 pg/kg body weight) or
placebo (vehicle). Blood from the tail vein was taken after 24 hours for the determination of circulating TNF-a (ELISA, R&D Systems) and fasting blood glucose and at 48 hours for measurement of fasting blood glucose. Two hours before administration of endotoxin or placebo, animals received dexamethasone (intramuscular 10 mg/kg body weight), synthetic relaxin-2 (Relaxera Pharmazeutische GmbH&Co.KG, Bensheim) as a subcutaneous infusion (4 pg shRIx/h) over 12 hours via osmotic Alzet minipumps, oral RU-486 (single dose of 10 mg/kg body weight), or combinations thereof (n = 5 animals per group). The results are shown in Figs. 10 and 11; *, p < 0.05 vs. control; #, p < 0.05 vs. endotoxin plus dexamethasone; Kruskal-Wallis ANOVA on ranks for global testing with posthoc Mann-Whitney U-tests for pairwise comparisons (Bonferroni-Holm adjustment of p).
(056) While dexamethasone markedly enhanced the endotoxin-related increase in blood glucose, reflecting the animal’s disease and hyperthermia response to endotoxin, relaxin-2 decreased glucose levels compared with endotoxin alone. This was true at both 24 and 48 hours after endotoxin. Oral administration of RU-486 inhibited the effects of relaxin-2 and dexamethasone by its antagonistic actions at the glucocorticoid receptor, as also the concentration of TNF-a in the circulation. In conclusion, human relaxin-2 attenuated the endotoxin-induced surge of circulating TNF-a in rats of both sexes. The effect could be identified as GR-dependent and comparable to that of dexamethasone, a classic glucocorticoid. However, unlike dexamethasone, relaxin-2 did not induce hyperglycemia which is a medically extremely important finding.
EXAMPLE 5 - Relaxin-2 furthers differentiation of naive T cells into regulatory T cells (Treg) in mice similar to glucocorticoids
(057) Mice of C57BI/6 background (each groups n=5) were intraperitoneally injected once daily for 3 consecutive days in the following experimental groups: synthetic human relaxin-2 (Relaxera) (10 micrograms/kg body weight), placebo (vehicle, sodium acetate), RU- 486 (2.5 mg/kg body weight), relaxin-2 plus RU-486. Thereafter, mice were sacrificed, their spleens were processed using standard procedures, and the percentage of spleen regulatory T cells (Treg) was analyzed by FACS. Treg cells were originally defined as characterized as CD4+FoxP3+ cells wherein FoxP3 (a Forkhead transcription factor) is the Treg master regulator. Regulatory T cells expressing the transcription factor Forkhead box P3 (FoxP3) are known to control immune responses and prevent autoimmunity.
(058) As shown in Fig. 12 the administration of relaxin-2 approximately doubled the percentage of regulatory T cells (CD4+FoxP3+ cells) as compared with placebo. The GR antagonist RU-486 did not affect the differentiation of T cell but when administered together with shRIx, its presence completely abrogated the relaxin-induced Treg increase. #, p < 0.05 vs. control; Kruskal-Wallis ANOVA on ranks for global testing with posthoc Mann-Whitney U- tests for pairwise comparisons (Bonferroni-Holm adjustment of p).
(059) These findings, therefore, substantiate a stimulatory effect of synthetic human relaxin-2 on the differentiation of peripheral (spleen) regulatory T cells (T reg) in mice and show that these effects are GR-dependent because they could be nullified by a GR-antagonist such as RU-486.
Discussion and Synopsis
(060) As mentioned above, glucocorticoids and corticosteroids are mainstays in the treatment of tissue-damaging autoimmune pathologies such as rheumatoid arthritis, and they are immunosuppressants following organ transplantation. An overwhelming amount of literature exists on the glucocorticoid-mediated regulation of the immune system and in particular on the glucocorticoid-mediated regulation of innate immunity and inflammation. The calcium-binding S100 proteins are universal markers for inflammation and of the innate immune system, notably calprotectin (the complex of S100A8 and S100A9) as well as S100A12. Generally, the presence of S100A12 and calprotectin indicate tissue injury, endothelial cell activation, and inflammation-mediated responses. Cell stress and/or inflammation induce the release of S100 proteins to acellular compartments where they bind cell surface receptors such as RAGE, TLR4, CD147, and GPCR. The interactions between the calcium-binding S100 proteins and their receptors activate intracellular signaling pathways such as AP1 and NFKB, which further initiates multiple cellular processes such as cell differentiation, migration, apoptosis, proliferation, and inflammation; activator protein 1 (AP1), extracellular signal-regulated protein kinase (ERK), G-protein-coupled receptor (GPCR); interleukin 1 (IL-1); interleukin 7 (IL-7), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IKBO), c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (P38), the receptor for advanced glycation end products (RAGE), toll-like receptor 4 (TLR4), TNF receptor-associated factor 2 (Traf2). Mammalian cells secrete calprotectin during the inflammatory response. The exact mechanism by which the complex of S100A8/S100A9 is secreted by mammalian cells during inflammation remains unknown. When released to the extracellular space, S100 proteins have activities in the regulation of immune homeostasis, post-traumatic injury, tissue damage, and inflammation. S100 proteins trigger inflammation through interacting with receptors RAGE and TLR4, and there is evidence that calprotectin (S100A8/S100A9) is an endogenous agonist of TLR4. Binding to TLR4 initiates a signaling cascade and regulates inflammation, cell proliferation, and differentiation in an NFKB- dependent manner. Apart from TLR4, RAGE has also been suggested to bind S100 proteins such as S100A7, S100A12, S100A8/A9 (calprotectin), and SWOB. By interacting with RAGE, S100 proteins activate NFKB, inducing the production of pro-inflammatory cytokines leading to the migration of neutrophils, monocytes, and macrophages. Extracellular S100 proteins are therefore involved in the regulation of cell apoptosis, migration of monocytes, macrophages, neutrophils, lymphocytes, myoblasts, epithelial cells, and endothelial cells. Consequently, the
levels of S100A8/A9 complex (calprotectin) and S100A12 in extracellular fluids can be used as biomarkers to assess the degree of inflammatory regulation and tissue injury.
(061) Liver transplantation and cold storage of livers were studied in mice having the same genetic setup. In this syngeneic mouse model, all immunological responses due to surgical trauma, cold storage, and ischemia injury are therefore mediated by the innate immune system whose effects can be dampened by the administration of corticosteroids. In this syngeneic mouse model, the administration of relaxin-2 at cold storage and/or at reperfusion proved cell-protective and markedly improved posttransplant liver function and survival (cf. Kageyama S et al. in Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside, Hepatology 2018, 258-273). Although the authors hypothesize a regulatory role of the relaxin-2-GR complex in the inflammatory injury in liver transplants, the impact of relaxin on the promotion of peripheral Treg cells and the activation and promotion of immune-suppressive Treg cells was not noted. With the knowledge of the present invention, continuous treatment of the recipient with relaxin- 2 is warranted as the activated peripheral Treg cells can suppress local immune responses and responses activated by any kind of tissue- and endothelial injury. A continuous administration of relaxin-2 is also warranted as relaxin-2 does not lead to gluconeogenesis as shown in Figs. 10 and 11.
(062) Concerning the anti-cancer activity of glucocorticoids, for example, De Bono et al. 2014 (Clin Cancer Res 2014, 20:1925-1934, US2006018910) disclose treating hormone- refractory prostate cancer patients with a combination of docetaxel, anti-IGF-IR antibodies, and dexamethasone, since the glucocorticoid receptor is upregulated in refractory prostate cancer cells, and therefore should be inhibited to impair the proliferation of these cancer cells (Ruhr et al., 2018. Clin Cancer Res 24: 927-938). It was found that activation of the glucocorticoid receptor leads to the acquisition of quiescence, subserved by cell cycle arrest through p57 and reprogramming of signaling orchestrated via Insulin Receptor Substrate 2 (IRS2)/Forkhead Box 01 (FOXOI). As synthetic relaxin-2 can be used as a substitute for dexamethasone, it may be favorably used in such therapy without incurring the adverse effects of glucocorticoids and their analogs.
(063) Boehnert MU in Relaxin as an additional protective model of isolate perfused rat liver, Ann N Y Acad Sci 2005, 1041 :434-440 and Bausys A et al. in Custodiol® supplemented with synthetic human relaxin decreases ischemia-reperfusion injury after porcine kidney transplantation, Int J Mol Sci. 2021 , 22, 11417 describe that relaxin in the perfusion solution reduces ischemia-reperfusion injury (IRI) after kidney or liver transplantation, and that relaxin-2 (RLX) upregulates the expressions of mitochondrial superoxide dismutase-2 (SOD2) and nuclear factor kappa B (NFKB), a regulator of innate immunity. The expression of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), which plays a role in apoptosis and necroptosis, was downregulated compared to controls. Also downregulated was the expression of mixed lineage kinase domain-like protein (MLKL), which plays a role in tumor necrosis factor (TNF)-induced necroptosis, and the number of caspase 3- and MPO-positive cells was also decreased in the grafts after static cold storage
in a solution containing relaxin-2. Static cold storage in a cardioplegic solution is the simplest, most convenient, and least expensive method of organ preservation in clinical practice. While relaxin-2 has been described for its antifibrotic, antioxidant, anti-inflammatory, and cytoprotective properties, there was no evidence that relaxin-2 can be used beneficially as a substitute for glucocorticoids without inducing their Cushingoid adverse effects, particularly gluconeogenesis, and its promotion of immune suppressive Treg cells was also not observed, which, however, makes relaxin-2 a broad-spectrum drug for tissue and endothelial injury, rather than a vasodilator additive in a perfusion solution to prevent ischemia-reperfusion injury.
Claims
CLAIMS A pharmaceutical composition for the treatment of a patient in need of prolonged dampening of inflammatory responses caused by the innate immune system when the side effects of steroid treatment are to be avoided, comprising an effective amount of synthetic human relaxin-2 and a pharmacological solvent, diluent, or excipient. The pharmaceutical composition as claimed in claim 1 for the treatment of a patient in need of long-term suppression of inflammatory responses caused by the innate immune system when the side effects of a glucocorticoid, corticosteroid, mineralocorticoid, or other steroid therapy are to be avoided, wherein the active pharmacological ingredient is synthetic human relaxin-2 in order not to provoke a manifestation or deregulation of diabetes, wound-healing disorder, and/or the symptoms of Cushing’s syndrome. The pharmaceutical composition according to claim 1 or 2 for the treatment of a patient or an organ of a patient or an allotransplant of a patient affected by tissue- or endothelium-damaging immune reactions and having one or more of the following increased clinical parameters compared to healthy individuals or organs: elevated serum HMGB1 (high-mobility group box protein); elevated serum sTLR4 (soluble Tolllike receptor-4), elevated serum sRAGE (soluble receptor of advanced glycation endproducts); elevated serum calprotectin and/or serum S100A12 or elevated calprotectin and/or S100A12 in the organ’s post-donation flush. The pharmaceutical composition of any preceding claim 1 to 3 for the treatment of a patient who is suffering from SIRS (systemic inflammatory response syndrome), autoimmune or rheumatic diseases, thyroiditis, gastritis, insulitis, sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, polyarthritis, ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic arthritis (PsA) and inflammatory types of arthritis, rheumatoid arthritis (RA), SARS-Covid 19 und SARS. The pharmaceutical composition of any claim 1 to 4, wherein the patient displays the following clinical criteria: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher according to the 2017 ACC/AHA Guidelines).
The pharmaceutical composition according to claim 3 for the treatment of an allograft recipient when one or more of the following four criteria are fulfilled: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml. The pharmaceutical composition according to claim 3 for the treatment of an allograft which has been subjected to increased immunological response reactions by the innate immune system and when one or more of the following criteria are observed in the blood flushed out after the organ donation: HMGB1 (high-mobility group box protein) > 2 ng/ml, sTLR4 (soluble Toll-like receptor-4) > 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) > 0.5 ng/ml, or calprotectin > 4 micrograms/ml. The pharmaceutical composition according to any claim 1 to 3 for the treatment of a patient in need of hormone-refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy through a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers; Kaposi Sarcoma, the synthetic human relaxin-2 being used as supplement and substitute of the glucocorticoid, cortisone, glucocorticoid receptor activating hormone or steroid. A method of treating a patient which comprises testing said patient for one or more of the following clinical parameters: serum HMGB1 (high-mobility group box protein) greater than or equal to 4 ng/ml; serum sTLR4 (soluble Toll-like receptor-4) greater than or equal to 0.5 ng/ml; serum sRAGE (soluble receptor of advanced glycation endproducts) greater than or equal to 2 ng/ml, and/or serum calprotectin greater than or equal to 10 micrograms/ml, and when given, administering to the patent an effective amount of synthetic human relaxin-2 within a pharmacological solvent, diluent, or excipient to dampen or suppress physiologic inflammatory reactions by the innate immune system. A method of treating a patient as claimed in claim 9, who is suffering from SIRS (systemic inflammatory response syndrome), autoimmune or rheumatic diseases, thyroiditis, gastritis, insulitis, sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, polyarthritis, ankylosing spondylitis (AS) and spondylarthritis, fibromyalgia, gout, infectious arthritis, lupus, systemic autoimmune disease, osteoarthritis (OA), psoriatic
arthritis (PsA) and inflammatory types of arthritis, rheumatoid arthritis (RA), SARS- Covid 19 und SARS. A method of treating a patient as claimed in claim 9, when the patient is suffering from immunological reactions by the innate immune system and/or displays the following clinical criteria: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (stage 1 or higher according to the 2017 ACC/AHA Guidelines). A method of treating a patient as claimed in claim 9, when the patient is suffering from inflammatory responses triggered by the innate immune system and/or requires suppression of inflammatory responses through a ligand-activated glucocorticoid receptor, wherein the active pharmacological ingredient is synthetic human relaxin-2 to avoid a manifestation or deregulation of diabetes, wound-healing disturbance, and/or the symptoms of Cushing’s syndrome. A method of treating a patient as claimed in claim 9, when the patient has received an allograft and requires suppression of the innate immune system and inflammatory responses, after testing the patient positive on one or more of the following medical criteria: serum HMGB1 (high-mobility group box protein) greater or equal to 2 ng/ml, serum sTLR4 (soluble Toll-like receptor-4) greater or equal to 0.25 ng/ml, serum sRAGE (soluble receptor of advanced glycation end-products) greater or equal to 0.5 ng/ml, and/or serum calprotectin greater or equal to 4 micrograms/ml. A method of treating a patient as claimed in claim 9, when the patient is in need of hormone-refractory cancer therapy, including, but not limited to prostate cancer, breast cancer, or a primary cancer therapy by a ligand-activated GR, including, but not limited to Multiple Myeloma, Hodgkin’s Disease, and other Lymphoid Cancers, Kaposi’s sarcoma, wherein synthetic human relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone. A method of treating a patient diagnosed as requiring immunosuppressive therapy, wherein synthetic relaxin-2 is used to supplement and/or replace glucocorticoid receptor-activating hormone to prevent or avoid a manifestation or deregulation of diabetes or symptoms of Cushing’s syndrome, particularly when the patient displays one or more of the following clinical features: pre-diabetes (HbA1C > 5.7 and < 6.5 %), obesity (BMI > 30 kg/m2), hypertension (Level 1 or higher according to the 2017 ACC/AHA guidelines).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102022121976 | 2022-08-31 | ||
DE102022121976.3 | 2022-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024047130A1 true WO2024047130A1 (en) | 2024-03-07 |
Family
ID=87933620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/073842 WO2024047130A1 (en) | 2022-08-31 | 2023-08-30 | Immunosuppressive medicament and method of treatment |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024047130A1 (en) |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003755A2 (en) | 1991-08-19 | 1993-03-04 | Genentech, Inc. | Use of relaxin in cardiovascular therapy and in the treatment of neurodegenerative diseases |
EP0793505A1 (en) | 1993-10-03 | 1997-09-10 | Knowhow Licensing & Knowhow Transfer B.V. | Medicaments comprising relaxin and their use |
EP0991947A1 (en) | 1997-06-23 | 2000-04-12 | The Regents Of The University Of California | Relaxin levels correlated to ivf/et pregnancy success |
WO2000048618A1 (en) | 1999-02-18 | 2000-08-24 | Yue Samuel K | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
WO2002040500A2 (en) | 2000-11-16 | 2002-05-23 | Immundiagnostik Ag | Method of prognosis and diagnosis of congestive heart failure |
EP1473034A1 (en) | 2003-03-17 | 2004-11-03 | Lagow GmbH | Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility |
US20060018910A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Inc | Combination treatment for non-hematologic malignancies |
DE102005040492A1 (en) | 2004-08-27 | 2006-03-16 | Immundiagnostik Ag | Perfusion- and preservation solution, useful for transplants and for perfusing and preserving organs for transplantation, comprises relaxin |
EP1696948A1 (en) | 2003-12-24 | 2006-09-06 | Bigazzi, Mario | Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
EP1765149A2 (en) | 2004-03-19 | 2007-03-28 | Kirk P. Conrad | Use of relaxin to increase arterial compliance |
WO2007115414A1 (en) | 2006-04-11 | 2007-10-18 | University Of Guelph | Modified h2 relaxin for tumor suppression |
EP1854476A2 (en) | 2000-02-09 | 2007-11-14 | Bas Medical, Inc. | Use of relaxin to treat diseases related to vasoconstriction |
EP1909809A2 (en) | 2005-06-13 | 2008-04-16 | Sky Biohealth Solutions, Inc. | Method and compositions for the treatment of diabetes and related complications |
EP2723366A1 (en) | 2011-06-24 | 2014-04-30 | Bold Venture LLC | Relaxin proteins for use in the diagnosis, prevention or treatment of multiple sclerosis |
EP2817026A1 (en) | 2012-02-22 | 2014-12-31 | Immundiagnostik AG | Relaxin for treating patients afflicted of impaired glucose tolerance |
EP2829280A1 (en) | 2008-05-16 | 2015-01-28 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with H2 relaxin |
EP3145534A1 (en) | 2014-05-23 | 2017-03-29 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
EP3347037A1 (en) | 2015-09-10 | 2018-07-18 | BvBiomed Ltd. | Novel therapy |
CA3139109A1 (en) * | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
-
2023
- 2023-08-30 WO PCT/EP2023/073842 patent/WO2024047130A1/en unknown
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003755A2 (en) | 1991-08-19 | 1993-03-04 | Genentech, Inc. | Use of relaxin in cardiovascular therapy and in the treatment of neurodegenerative diseases |
EP0793505A1 (en) | 1993-10-03 | 1997-09-10 | Knowhow Licensing & Knowhow Transfer B.V. | Medicaments comprising relaxin and their use |
EP0991947A1 (en) | 1997-06-23 | 2000-04-12 | The Regents Of The University Of California | Relaxin levels correlated to ivf/et pregnancy success |
WO2000048618A1 (en) | 1999-02-18 | 2000-08-24 | Yue Samuel K | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
EP1854476A2 (en) | 2000-02-09 | 2007-11-14 | Bas Medical, Inc. | Use of relaxin to treat diseases related to vasoconstriction |
WO2002040500A2 (en) | 2000-11-16 | 2002-05-23 | Immundiagnostik Ag | Method of prognosis and diagnosis of congestive heart failure |
EP1473034A1 (en) | 2003-03-17 | 2004-11-03 | Lagow GmbH | Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility |
EP1696948A1 (en) | 2003-12-24 | 2006-09-06 | Bigazzi, Mario | Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
EP1765149A2 (en) | 2004-03-19 | 2007-03-28 | Kirk P. Conrad | Use of relaxin to increase arterial compliance |
US20060018910A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Inc | Combination treatment for non-hematologic malignancies |
DE102005040492A1 (en) | 2004-08-27 | 2006-03-16 | Immundiagnostik Ag | Perfusion- and preservation solution, useful for transplants and for perfusing and preserving organs for transplantation, comprises relaxin |
EP1909809A2 (en) | 2005-06-13 | 2008-04-16 | Sky Biohealth Solutions, Inc. | Method and compositions for the treatment of diabetes and related complications |
WO2007115414A1 (en) | 2006-04-11 | 2007-10-18 | University Of Guelph | Modified h2 relaxin for tumor suppression |
EP2829280A1 (en) | 2008-05-16 | 2015-01-28 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with H2 relaxin |
EP2723366A1 (en) | 2011-06-24 | 2014-04-30 | Bold Venture LLC | Relaxin proteins for use in the diagnosis, prevention or treatment of multiple sclerosis |
EP2817026A1 (en) | 2012-02-22 | 2014-12-31 | Immundiagnostik AG | Relaxin for treating patients afflicted of impaired glucose tolerance |
EP3145534A1 (en) | 2014-05-23 | 2017-03-29 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
EP3347037A1 (en) | 2015-09-10 | 2018-07-18 | BvBiomed Ltd. | Novel therapy |
US20190000927A1 (en) * | 2015-09-10 | 2019-01-03 | Bv Biomed Ltd | Novel therapy |
CA3139109A1 (en) * | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
Non-Patent Citations (46)
Title |
---|
ALEXIOU K ET AL.: "Relaxin is a candidate drug for lung preservation: relaxin induced protection of rat lungs from ischemia-reperfusion injury", J HEART LUNG TRANSPLANT, vol. 29, 2010, pages 454 - 460, XP026981546 |
ANTON NESCHADIM ET AL: "Targeting the relaxin hormonal pathway in prostate cancer", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 137, no. 10, 22 July 2014 (2014-07-22), pages 2287 - 2295, XP071288400, ISSN: 0020-7136, DOI: 10.1002/IJC.29079 * |
BAUSYS A ET AL.: "Custodiol@ supplemented with synthetic human relaxin decreases ischemia-reperfusion injury after porcine kidney transplantation", INT J MOL SCI, vol. 22, 2021, pages 11417 |
BAUSYS A ET AL.: "Custodiol@ supplemented with synthetic human relaxin decreases ischemia-reperfusion injury after porcine kidney transplantation", INT J MOL SCI., vol. 22, 2021, pages 11417 |
BITTO ALESSANDRA ET AL: "Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice", CLINICAL SCIENCE., vol. 125, no. 12, 2 August 2013 (2013-08-02), GB, pages 575 - 585, XP093092152, ISSN: 0143-5221, Retrieved from the Internet <URL:https://watermark.silverchair.com/cs1250575.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAABE0wggRJBgkqhkiG9w0BBwagggQ6MIIENgIBADCCBC8GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMV4sLMWwTC0dguPrYAgEQgIIEAITgy_Aq_Q6tUOVP1YV7jilIPQ_nvser6HoKvIUprYNR2wA4uRT9XeNGUdHcqnV8YHJzyb4TRwx9vGQn6jQicZSeW0> DOI: 10.1042/CS20130105 * |
BOEHNERT MU: "Relaxin as an additional protective model of isolate perfused rat liver", ANN N Y ACAD SCI, vol. 1041, 2005, pages 434 - 440, XP071401512, DOI: 10.1196/annals.1282.065 |
BOEHNERT MU: "Relaxin as an additional protective model of isolate perfused rat liver", ANN NYACAD SCI, vol. 1041, 2005, pages 434 - 440, XP071401512, DOI: 10.1196/annals.1282.065 |
BONNER JEFFREY S. ET AL: "Relaxin Treatment Reverses Insulin Resistance in Mice Fed a High-Fat Diet", DIABETES, vol. 62, no. 9, 15 August 2013 (2013-08-15), US, pages 3251 - 3260, XP093092583, ISSN: 0012-1797, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749347/pdf/3251.pdf> DOI: 10.2337/db13-0033 * |
CARI LUIGI ET AL: "Context-Dependent Effect of Glucocorticoids on the Proliferation, Differentiation, and Apoptosis of Regulatory T Cells: A Review of the Empirical Evidence and Clinical Applications", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 5, 6 March 2019 (2019-03-06), pages 1142, XP093092989, DOI: 10.3390/ijms20051142 * |
CHEN FENG ET AL: "The significance of serum HMGB1 level in humans with acute paraquat poisoning", SCIENTIFIC REPORTS, vol. 9, no. 1, 15 May 2019 (2019-05-15), XP093092364, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-019-43877-1> DOI: 10.1038/s41598-019-43877-1 * |
CLUTTER WILLIAM E: "SCIENCE OF MEDICINE Screening for Cushing's Syndrome in an Era of Epidemic Obesity", MO MED. 2011 MAR-APR; 108(2): 104-106., 1 March 2011 (2011-03-01), pages 104 - 106, XP093092575, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189156/pdf/ms108_p0104.pdf> [retrieved on 20231017] * |
COLLINO M ET AL.: "Acute treatment with relaxin protects the kidney against ischemia-reperfusion injury.", J CELL MOL MED, vol. 17, 2013, pages 1494 - 1505 |
COULSON CC ET AL.: "Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model", OBSTETRICS & GYNECOLOGY, vol. 87, no. 4, 1996, pages 610 - 612 |
DE BONO ET AL., CLIN CANCER RES, vol. 20, 2014, pages 1925 - 1934 |
DILASCIO G ET AL.: "Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a ratmodel", TEX HEART INST J, vol. 39, 2012, pages 488 - 499 |
DSCHIETZIG T ET AL.: "Autoregulation of human relaxin-2 gene expression critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter", REGUL PEPT., vol. 155, 2009, pages 163 - 73, XP026158590, DOI: 10.1016/j.regpep.2009.03.001 |
DSCHIETZIG T ET AL.: "Plasma levels and myocardial expression of relaxin-2 are increased in human heart failure", CIRCULATION, vol. 102, no. 18, 2000, pages 594 |
DSCHIETZIG T ET AL.: "Relaxin: a pregnancy hormone as a central player of body fluid and circulation homeostasis", CMLS, vol. 60, 2003, pages 688 - 700, XP008145479, DOI: 10.1007/s00018-003-2169-x |
DSCHIETZIG T ET AL.: "Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics", PHARMACOL THER, vol. 112, 2006, XP025038563, DOI: 10.1016/j.pharmthera.2006.03.004 |
DSCHIETZIG T ET AL.: "RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway", REGUL PEPT, vol. 154, 2009, pages 77 - 84, XP026079176, DOI: 10.1016/j.regpep.2008.11.010 |
DSCHIETZIG T ET AL.: "The pregnancy hormone relaxin binds to and activates the human glucocorticoid receptor", ANN NYACAD SCI., vol. 1041, 2005, pages 256 - 71, XP071401576, DOI: 10.1196/annals.1282.039 |
DSCHIETZIG T ET AL: "RXFP1-inactive relaxin activates human glucocorticoid receptor: Further investigations into the relaxin-GR pathway", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 154, no. 1-3, 10 April 2009 (2009-04-10), pages 77 - 84, XP026079176, ISSN: 0167-0115, [retrieved on 20081207], DOI: 10.1016/J.REGPEP.2008.11.010 * |
DSCHIETZIG TB ET AL.: "Identification of the pregnancy hormone relaxin as a glucocorticoid receptor agonist", FASEB J, vol. 18, 2004, pages 1536 - 1538 |
FAKHRY NOURAN ET AL: "Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma", WSPÓŁCZESNA ONKOLOGIA, vol. 24, no. 3, 30 October 2020 (2020-10-30), pages 157 - 162, XP093092375, ISSN: 1428-2526, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670186/pdf/WO-24-42187.pdf> DOI: 10.5114/wo.2020.100270 * |
FEIJÓO-BANDÍN SANDRA ET AL: "Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives", FRONTIERS IN PHYSIOLOGY, vol. 8, 18 August 2017 (2017-08-18), XP093092574, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563388/pdf/fphys-08-00599.pdf> DOI: 10.3389/fphys.2017.00599 * |
HEMMERLING M ET AL.: "Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases", J. MED. CHEM., vol. 60, no. 20, 2017, pages 8591 - 8605, XP055825954, DOI: 10.1021/acs.jmedchem.7b01215 |
HISAW FL: "xperimental relaxation of the pubic ligament of the guinea pig", PROC. SOC. EXP. BIOL. MED., vol. 23, 1926, pages 661 - 663 |
JAKUBAUSKIENE L ET AL.: "Relaxin positively influences ischemia-reperfusion injury in solid organ transplantation: a comprehensive review", INT J MOL SCI, vol. 21, no. 2, 2020, pages 631ff |
JARLBORG MATTHIAS ET AL: "Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis", ARTHRITIS RESEARCH & THERAPY, vol. 22, no. 1, 6 May 2020 (2020-05-06), XP093092381, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s13075-020-02190-3/fulltext.html> DOI: 10.1186/s13075-020-02190-3 * |
KAGEYAMA S ET AL., RELAXIN IN LIVER TRANSPLANTATION: A PERSONAL PERSPECTIVE MOL CELL ENDOCRINOL., vol. 487, 2019, pages 75 - 79 |
KAGEYAMA S ET AL.: "Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor From bench-to-bedside", HEPATOLOGY, vol. 258, 2018, pages 273 |
KAZUO NAKAMURA ET AL: "Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON, GB, vol. 23, no. 5, 6 October 2006 (2006-10-06), pages 368 - 371, XP072257104, ISSN: 1520-7552, DOI: 10.1002/DMRR.690 * |
LIANG KAI ET AL: "Analysis of Cardiovascular Risk Factors in Newly Defined Stage 1 Hypertension among Chinese on the Basis of the 2017 ACC/AHA Hypertension Guidelines", BIOMEDICAL AND ENVIRONMENTAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 33, no. 1, 1 January 2020 (2020-01-01), pages 48 - 52, XP086077885, ISSN: 0895-3988, [retrieved on 20200305], DOI: 10.3967/BES2020.006 * |
LORENZI R. ET AL: "Anti-sRAGE autoimmunity in obesity: Downturn after bariatric surgery is independent of previous diabetic status", DIABETES & METABOLISM, vol. 40, no. 5, 2 June 2014 (2014-06-02), AMSTERDAM, NL, pages 356 - 362, XP093092242, ISSN: 1262-3636, DOI: 10.1016/j.diabet.2014.04.008 * |
MARGARITA DOMINQUEZ-VALLARDAVID A. HAFLER: "Regulatory T cells in autoimmune disease", NATURE IMMUNOLOGY, vol. 19, 2018, pages 665 - 673, XP036533612, DOI: 10.1038/s41590-018-0120-4 |
MARTIN BRIAN ET AL: "Relaxin reverses inflammatory and immune signals in aged hearts", PLOS ONE, vol. 13, no. 1, 18 January 2018 (2018-01-18), pages e0190935, XP093092153, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0190935&type=printable> DOI: 10.1371/journal.pone.0190935 * |
MASINI E. ET AL.: "Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide", ENDOCRINOLOGY, vol. 138, 1997, pages 4713 - 4720 |
NICOLAIDES N ET AL., GLUCOCORTICOID RECEPTOR, 2021 |
RAZEGHI P ET AL.: "Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading", CARDIOLOGY, vol. 97, no. 4, 2002, pages 203 - 9 |
RUHR ET AL., CLIN CANCER RES, vol. 24, 2018, pages 927 - 938 |
SAPUTRA GUSTI NOOR RAMADANY ET AL: "Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study", ANNALS OF MEDICINE AND SURGERY, vol. 74, 29 January 2022 (2022-01-29), XP093092260, ISSN: 2049-0801, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800495/pdf/main.pdf> DOI: 10.1016/j.amsu.2022.103303 * |
SHOICHI KAGEYAMA ET AL: "Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 68, no. 1, 10 May 2018 (2018-05-10), pages 258 - 273, XP071563375, ISSN: 0270-9139, DOI: 10.1002/HEP.29787 * |
TAMAKI N ET AL., AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 294, 2008 |
TEICHMANN SL ET AL.: "Relaxin: a review of the biology and potential role in treating heart failure", CURR HEART FAIL REP, vol. 7, 2010, pages 75 - 82 |
ZHANG XIMEI ET AL: "The progress and prospect of regulatory T cells in autoimmune diseases", JOURNAL OF AUTOIMMUNITY, vol. 111, 15 April 2020 (2020-04-15), GB, pages 102461, XP093092730, ISSN: 0896-8411, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/272429/1-s2.0-S0896841120X00060/1-s2.0-S0896841120300779/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEIr//////////wEaCXVzLWVhc3QtMSJHMEUCIAMvffU0zPDooG/BUICY7myfhNSwAWaEcxPcWQJV6Y1OAiEAyQz3eFduTRA4Bg+09Jh6jyQ/R+Ol9VBopv08kvyPsJsqvAUIov//////////ARAFGgwwNTkwMDM1N> DOI: 10.1016/j.jaut.2020.102461 * |
ZUIDEMA MOZOW Y ET AL: "Ischemia/reperfusion injury: The role of immune cells", WORLD JOURNAL OF CARDIOLOGY, vol. 2, no. 10, 26 October 2010 (2010-10-26), pages 325, XP093092115, ISSN: 1949-8462, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999044/pdf/WJC-2-325.pdf> DOI: 10.4330/wjc.v2.i10.325 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nathan and et al. | Estrogens and atherosclerosis | |
Biller et al. | Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement | |
Jara et al. | Prolactin and autoimmunity | |
Schanton et al. | Involvement of leptin in the molecular physiology of the placenta | |
Koh | Effects of estrogen on the vascular wall: vasomotor function and inflammation | |
Ozata et al. | Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects | |
Bandyopadhyay et al. | Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance | |
Marzolla et al. | The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway | |
Forhead et al. | Plasma leptin concentration in fetal sheep during late gestation: ontogeny and effect of glucocorticoids | |
Zhang et al. | Bile acids evoke placental inflammation by activating Gpbar1/NF-κ B pathway in intrahepatic cholestasis of pregnancy | |
Xue et al. | The role of dendritic cells regulated by HMGB1/TLR4 signalling pathway in myocardial ischaemia reperfusion injury | |
Marik | Endocrinology of the stress response during critical illness | |
Li et al. | SGK1 inhibitor reverses hyperglycemia partly through decreasing glucose absorption | |
Bae et al. | Regulation of IGFBP-1 in metabolic diseases | |
Selzman et al. | The biology of estrogen-mediated repair of cardiovascular injury | |
Yeager et al. | Cortisol antiinflammatory effects are maximal at postoperative plasma concentrations | |
Li et al. | Short‐term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice | |
EP2882448B1 (en) | KGF/FGF7 for use in the treatment of vaginal atrophy induced by chemotherapy | |
Tang et al. | Osteoprotegerin promotes islet β cell proliferation in intrauterine growth retardation rats through the PI3K/AKT/FoxO1 pathway | |
Annetta et al. | Use of corticosteroids in critically ill septic patients: a review of mechanisms of adrenal insufficiency in sepsis and treatment | |
WO2010131038A2 (en) | Steroid containing composition and uses thereof | |
WO2024047130A1 (en) | Immunosuppressive medicament and method of treatment | |
Shafighi et al. | Topical application of 17β‐estradiol (E 2) improves skin flap survival through activation of endothelial nitric oxide synthase in rats | |
WO2016131943A1 (en) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes | |
P Sarapultsev et al. | Effect of a new class of compounds of the group of substituted 5R1, 6H2-1, 3, 4-thiadiazine-2-amines on the inflammatory and cytokine response in experimental myocardial infarction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23765189 Country of ref document: EP Kind code of ref document: A1 |